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ABSTRACT 
Isolated primary dystonia describes a group of inherited movement disorders 
characterized by sustained muscle contractions traditionally thought to manifest in the 
absence of neurodegeneration. The most common form, DYT1 Dystonia, is caused by a 
dominant mutation in the gene TOR1A. This mutation is a 3 base pair in-frame deletion 
that results in the loss of a single glutamic acid “∆E” from the encoded protein, torsinA. 
Understanding loss-of-function (LOF) and gain-of-function (GOF) properties of the ∆E 
mutation is critical for defining disease mechanisms and developing future therapeutics. 
To evaluate the pathogenesis of ∆E-torsinA in vivo I generated a novel conditional knock-
in mouse model that allows for anatomical- and temporal-specific expression of ∆E-
Tor1a via Cre recombination. I evaluated viability, neuropathology, and motor 
phenotypes of CNS-specific Tor1ai-∆E/- and Tor1ai-∆E/i-∆E littermates and found no 
evidence for ∆E GOF toxicity. Additionally, I demonstrated the power of this model by 
addressing a popular circuit level hypothesis in our field: cerebellar dysfunction explains 
reduced penetrance of DYT1 dystonia. I found that hindbrain specific induction of the 
DYT1 genotype is not sufficient to produce a mouse with an abnormal motor behavior. 
These in vivo findings support strictly LOF effects for the ∆E mutation at the molecular 
and circuit level.  
!xvi
TorsinA LOF mouse models reveal that discrete sensorimotor nuclei experience neural 
toxicity, evidence of altered protein quality control, and cell death. With this knowledge, I 
developed and characterized an in vitro cortical neuron culture that recapitulates in vivo 
LOF phenotypes as well as cell-type specific susceptibility. Identification of a cortical 
subtype specifically vulnerable to torsinA LOF sheds light on mechanisms behind 
abnormal motor output observed in disease-manifesting mouse models, thus introducing 
new hypotheses for circuit dysfunction in DYT1 dystonia patients.  
Together these in vivo and in vitro approaches deliver new insights on the molecular 
consequences of torsinA dysfunction. These tools will be useful in future studies that aim 
to identify mechanisms underlying the unique vulnerability of discrete cell types to 
torsinA LOF and the impact of neural development on the manifestation of dystonia. 
!xvii
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CHAPTER I 
Genetics and Molecular Mechanisms of Primary Dystonia 
Introduction 
Dystonia is defined as a sustained or intermittent involuntary movement that typically 
manifests as twisting but may also appear tremulous. Dystonic movements are frequently 
repetitive and patterned, and can cause abnormal postures (Albanese et al., 2013). These 
involuntary movements are typically activated and exacerbated by voluntary actions. 
Dystonic movements can occur from damage to essentially any component of the motor 
system, though are classically associated with putaminal damage. Essentially any 
pathological process that damages the motor system can cause dystonia, including 
neurodegenerative disease, stroke, and trauma. These forms are traditionally referred to 
as “secondary” dystonias, and are typically accompanied by additional neurological signs 
and symptoms. In contrast, dystonic movement may occur in isolation in the absence of 
identifiable CNS injury. This situation, termed “primary” dystonia, may begin during 
childhood or in adult subjects. Onset in childhood frequently results from dominantly 
 Portions of this chapter are currently in press: Weisheit CE, Dauer WT. Neurogenetics - 1
Primary Dystonia. In: D. Geschwind, HL Paulson, C Klein Editor(s), Handbook of Clinical 
Neurology, Elsevier, Amsterdam.
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inherited mutations, whereas nearly all cases of adult-onset disease are sporadic and not 
linked to known genetic causes. 
Most genetic causes of primary dystonia have been identified using traditional methods 
such as linkage analysis and positional cloning (Fuchs et al., 2009; Ozelius et al., 1997). 
More recently, whole exome sequencing has been used to successfully identify genes 
(Fuchs et al., 2013; Ichinose et al., 1994). Although grouped together under the umbrella 
of “dystonia,” genetic etiology strongly influences the natural history of different forms 
of the disease. While our understanding of the pathogenesis and pathophysiology of 
dystonia is still in its infancy, study of the monogenic forms of dystonia is beginning to 
identify cellular mechanisms and vulnerable cell types and circuits, which in turn are 
leading to new concepts for targeted therapeutics.  
In this chapter we focus on four monogenic forms of primary dystonia [Locus (GENE, 
protein)]; DYT1 (TOR1A, torsinA), DYT6 (THAP1, THAP1), DYT5 (GCH1, GTP 
cyclohydrolase 1), and DYT25 (GNAL, Gα(olf)) (Figure I.1). Mutation of the TOR1A 
gene was the first identified genetic cause of “pure” primary dystonia (DYT5 subjects 
may exhibit some parkinsonism). Accordingly, this form of dystonia has attracted wide 
interest and considerable knowledge has been gained about the cell biological roles of 
torsinA and the effects of the DYT1 mutation, and most animal models of primary 
dystonia are DYT1-based. DYT6 is phenomenologically similar to DYT1 dystonia, and 
is caused by mutations in the transcription factor THAP1. Because DYT5 subjects may 
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also exhibit parkinsonism, it is technically a “secondary” form of the disease. However, 
we consider it here because it and DYT25 encode genes involved in dopaminergic 
neurotransmission, and therefore provide insight into the neurochemical pathogenesis of 
the disease. While it is tempting to synthesize different aspects of what has been learned 
about distinct genetic forms of dystonia into a larger picture, little evidence exists to link 
these different forms of the disease, at a cellular, neurochemical, or circuit level. We 
therefore believe it is premature to generalize findings between genetic forms, despite the 
apparent likelihood that some common downstream circuit abnormalities are shared 
between different genetic forms of the disease.  
DYT1 DYSTONIA – EARLY-ONSET GENERALIZED DYSTONIA 
Etiology and Epidemiology  
DYT1 dystonia is caused by a dominantly inherited mutation in TOR1A (chromosome 
9q34) (Ozelius et al., 1997). The mutation is a three-nucleotide deletion that results in the 
loss of a single glutamic acid (∆E) from the encoded protein, torsinA. Notably, all 
patients carry the identical mutation, which has arisen independently in unrelated 
individuals from diverse ethnic backgrounds (Hjermind et al., 2002; Klein et al., 1998; 
Ikeuchi et al., 2002). There are rare examples of other monogenic diseases arising from a 
recurrent discrete mutation, including achondroplasia (Bellus et al., 1995). The reasons 
for recurrent discrete mutations of this type are not defined clearly, but include the 
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possibility of an error during DNA replication caused by susceptible DNA structure 
(Klein et al., 1998).   
The DYT1 mutation is most common in Ashkenazi Jewish populations, where its 
frequency has been estimated to be as high as 1/2,000–up to ten times higher than in 
other ethnic backgrounds (Frederic et al., 2007; Risch et al., 1995). The DYT1 mutation 
arose as a founder mutation in the Ashkenazi Jewish population ~350 years ago (Risch et 
al., 1995), which in part accounts for the continued increased prevalence of the mutation 
in the population (Ozelius et al., 2011). A potential role for TOR1A polymorphisms in 
adult-onset idiopathic dystonia has been suggested, but reports conflict on this question. 
Some work finds that specific TOR1A haplotypes are increased in idiopathic dystonia 
cohorts (Clarimon et al., 2005; Clarimon et al., 2007; Hague et al., 2006; Sibbing et al., 
2003) whereas SNPs located in the 3’ UTR are reported to be protective against 
developing sporadic focal dystonia (Kamm et al., 2006; Sharma et al., 2010). 
The DYT1 mutation exhibits reduced penetrance (~30%) and variable expressivity 
(further discussed below in “Clinical Presentation”). One SNP, D216H, has been 
identified as a factor contributing to the decreased penetrance (Ozelius et al., 1997; 
Frederic et al., 2009). The presence of the D216H allele is associated with reduced 
penetrance when expressed in trans to the DYT1 mutation. The prevalence of this 
polymorphism is low, however, so its contribution to the reduced penetrance is small 
(Risch et al., 2007; Bruggemann et al., 2009). The role of D216H in idiopathic dystonia is 
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unclear. One report suggests that it may be a risk factor for subjects with cervical 
dystonia, writer’s cramp, and blepharospasm that have a positive family history of 
dystonia (Bruggemann et al., 2009). Other work has failed to identify increases in the 
frequency of the D216H allele in subjects with idiopathic adult onset dystonia (Sharma et 
al., 2010; Bruggemann et al., 2009; Sibbing et al., 2003). Cellular studies show that over-
expressing either the D216H SNP or the ∆E mutation resulted in characteristic torsinA 
inclusions (Kock et al., 2006). Interestingly, when these over-expression constructs were 
combined, inclusions were reduced, consistent with the notion that D216H somehow 
protects against the deleterious cellular effect of pathogenic torsinA.  
Clinical Presentation 
The symptoms of DYT1 most often begin in one limb during early adolescence (Greene 
et al., 1995; Bressman et al., 1994). Over the next five years, symptoms typically spread 
to involve additional body parts, including other limbs, trunk and head. Up to 50% of 
patients may develop generalized involvement. Median age at onset is 13 years old, but 
essentially always before 26 years of age. Those carrying the disease mutation who reach 
the age of 27 without displaying symptoms are labeled as “non-manifesting” carriers, 
since they almost never develop symptoms subsequently. A characteristic pattern of 
spread is from one leg to another. Bilateral leg (and trunk) involvement may be 
particularly disabling, rendering patients unable to walk without assistance. Notably, 
cranial or laryngeal involvement is considerably less common in DYT1 dystonia, being 
present in ~25% and ~12% of patients respectively (Gambarin et al., 2006; Fasano et al., 
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2006; Bressman et al., 2002; Kramer et al., 1994; Bressman et al., 1994). The presence of 
a single dystonia-causing mutation in TOR1A has enabled readily available and 
straightforward genetic testing. Based on the natural history of the disease, testing for the 
DYT1 mutation for diagnosis is recommended only in patients with dystonia onset before 
age 26, unless additional information clearly indicates the possibility of the mutation 
(e.g., a clear family history of dystonia) (Bressman et al., 2002). 
   
Neuroimaging and clinical electrophysiological studies identify abnormalities in all 
DYT1 mutation carriers–regardless of clinical status. All DYT1 mutation carriers show 
increased metabolic activity in lentiform nuclei, cerebellum, and supplementary motor 
areas (Eidelberg et al., 1998), have reduced cortical inhibition (Edwards et al., 2003), and 
display sensorimotor cortex white matter disturbances in cerebellothalamic tracts (Carbon 
et al., 2004; Argyelan et al., 2009). Additional network abnormalities are observed in 
manifesting patients, indicating a requirement for other inimical factors (e.g., 
environmental, genetic) to reach a pathological threshold. Paradoxically, diffusion tensor 
imaging (DTI) studies find that non-manifesting carriers show greater abnormalities (e.g., 
in thalamocortical pathways), raising the possibility that this ‘second hit’ blocks the 
effects of a cerebellothalamic abnormality found in all mutation carrying patients 
(Argyelan et al., 2009). Germline ∆E-Tor1a knock-in mice (which do not display overt 
abnormal motor behavior (Tanabe et al., 2012)) exhibit DTI abnormalities similar to non-
manifesting patients, indicating that these mice model the non-manifesting human carrier 
state (Ulug et al., 2011). 
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Pathogenesis 
TorsinA is a member of a superfamily of molecular chaperones known as ATPases 
Associated with a variety of cellular Activities (AAA+ ATPases). TorsinA (and other 
torsinA family members) are the only AAA+ proteins known to reside within the 
endoplasmic reticulum-nuclear envelope lumen (ER-NE). AAA+ ATPases harness energy 
of ATP hydrolysis to facilitate conformational changes in substrates or alter interactions 
within protein complexes. Although binding partners for torsinA have been identified 
within both the ER and NE lumen (LULL1, LAP1, SUN1, printor, and nesprins), bona 
fide substrates for torsinA remain unknown (Giles et al., 2009; Jungwirth et al., 2011; 
Nery et al., 2008; Goodchild & Dauer, 2005). The reader is referred to a recent extensive 
review of torsinA function within the ER-NE space (Dauer, 2014)–here we will focus on 
more recent developments.  
LAP1 and LULL1 are transmembrane proteins whose luminal domains mediate a direct 
physical interaction with torsinA (Goodchild & Dauer, 2005). In vitro studies demonstrate 
that torsinA itself is inactive, but that its ATPase activity is strongly activated by LAP1 
and LULL1 (Zhao et al., 2013). In contrast, these proteins are largely ineffective in 
activating DYT1 mutant torsinA. These biochemical data are consistent with mouse 
genetic experiments demonstrating that the ∆E mutation impairs torsinA function 
(Goodchild et al., 2005; Liang et al., 2014). The activation of torsinA by LAP1 or 
LULL1, which reside respectively in the NE and ER, suggest a model whereby each of 
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these molecules controls torsinA activity in a distinct cellular compartment through 
membrane recruitment and binding. Subsequent work by two groups has clarified further 
the relationship of LAP1 and LULL1 in torsinA biology (Brown et al., 2014; Sosa et al., 
2014). AAA+ proteins typically assemble into hexameric rings, and the interactions 
between neighboring molecules (“protomers”) are essential for proper ATPase function 
(Iyer et al., 2004). ATPase activation of AAA+ proteins typically relies on an “arginine 
finger” residue in the neighboring protomer (Ogura et al., 2004). Crystallization of LAP1 
demonstrated that it assumes an atypical AAA+ protein fold (Sosa et al., 2014), and 
additional studies showed that LAP1 (or LULL1) hetero-oligomerize with torsinA to 
form an active AAA+ complex (Brown et al., 2014). In fact, torsinA was found to lack 
the arginine finger present in nearly all other AAA+ proteins (Brown et al., 2014), and 
this essential residue was found to be supplied by LAP1 (or LULL1) within the 
heterooligomeric structure (Brown et al., 2014; Sosa et al., 2014). In this manner, LAP1 
and LULL1 appear to act like the GAP protein that is known to provide a critical arginine 
finger that aids in stabilizing the transition state of the GTPase during GTP hydrolysis 
(Scheffzek et al., 1998; Brown et al., 2014). This work also appears to provide molecular 
insight into the mechanism through which the ∆E mutation impairs torsinA function. The 
∆E mutation maps to the interface between torsinA and LAP1/LULL1, so appears to 
cause misalignment between protomers (Zhao et al., 2013). This misalignment likely 
accounts for the loss of affinity between mutant torsinA and LAP1/LULL1, and in loss of 
complex formation and function (Kock et al., 2006; Brown et al., 2014; Sosa et al., 2014; 
Zhu et al., 2010). A homozygous mutation in the gene encoding LAP1 has been identified 
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in a child with severe dystonia, a finding consistent with the importance of the LAP1-
torsinA interaction and highlighting a potentially key role for LAP1 in dystonia 
pathogenesis (Dorboz et al., 2014). 
Within the ER, several recent observations, building upon earlier work (reviewed in 
(Dauer, 2014)), point to a role for torsinA in protein quality control. A role in the 
endoplasmic reticulum-associated degradation (ERAD) pathway is suggested by the 
association of torsinA with ERAD components Derlin-1, VIMP, and p97 (Nery et al., 
2011). Cellular studies show torsinA alleviates ER stress and is necessary for ERAD 
mediated degradation of mutant CFTR (Nery et al., 2011). Also consistent with this 
notion is the abnormal accumulation of perinuclear ubiquitin in neurons from mice in 
which torsinA has been conditionally deleted from the CNS (Liang et al., 2014). This 
finding also occurs in mice that selectively express the isolated DYT1 mutant torsinA 
within the CNS, and in both lines is associated with the abnormal perinuclear 
accumulation of the E3 ubiquitin ligase Hrd1, a key ERAD component. Taken together 
these data suggest torsinA may play a significant role in coordinating ERAD processes.  
A considerable body of evidence supports a role for torsinA in the NE (reviewed in 
(Dauer, 2014)) and lack of normal torsinA function results in NE membrane 
abnormalities, termed NE buds (Goodchild et al., 2005). The single torsinA homolog in 
drosophila, Torsin, recently was found to play a major role in a newly discovered 
mechanism that allows for nuclear export of large RNPs (ribonucleoprotein particles) 
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termed megaRNPs (Speese et al., 2012; Jokhi et al., 2013). Export of these large granules 
requires budding of the NE and is essential for proper synapse development (Jokhi et al., 
2013). Interestingly, electron microscopy of drosophila mutants demonstrates NE buds 
appear similar to mouse neurons lacking torsinA (Jokhi et al., 2013). These data implicate 
an intriguing new direction for torsinA cell biology in controlling a novel trans-
membrane vesicular transport pathway. In related nuclear membrane work, loss of the 
torsinA homolog in C. elegans, OOC-5, causes NE buds and abnormal nuclear pore 
complex formation and function (VanGompel et al., 2015). In yeast, several nuclear pore 
mutants cause nuclear membrane abnormalities (e.g. (Wente & Blobel, 1993; Wente & 
Blobel, 1994; Zabel et al., 1996)), including bud like structures. A potential interpretation 
of this work is that torsinA is involved in insertion of nuclear pores into the interphase 
nuclear membrane, and that NE buds represent a “stalled” intermediate structure. 
Explorations into how torsinA participates in either of these processes in mammalian 
neurons remains necessary to fully understand the implications of this work for DYT1 
pathogenesis.  
Despite increasing understanding of the cellular roles for torsinA, efforts to translate this 
information into an animal model of the disease with overt abnormal movements similar 
to DYT1 subjects had until recently been unsuccessful (Dauer, 2014; Pappas et al., 2014). 
This situation changed with publication of a series of torsinA mutant mice that develop 
overt twisting movements during postnatal CNS maturation (Liang et al., 2014). The 
induction of torsinA loss-of-function early during CNS development appears to be a key 
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factor in the success of these models, implicating an important role for torsinA function 
in early CNS maturation. The most notable of these lines was generated by selectively 
expressing the isolated DYT1 mutant torsinA within the CNS. These CNS “selective 
knock-in” (SKI) mice develop a range of abnormal twisting movements starting between 
the first and second postnatal week, but these movements stabilize and remain relatively 
fixed for the life of the animal, even into advanced age. Surprisingly, there is 
neurodegeneration in these mice that involves a discrete set of motor structures (including 
layer V cortex, VPN thalamus, red nucleus, deep cerebellar nuclei, globus pallidus and 
substantia nigra pars reticulata). Similar to the motor symptoms, this cell loss occurs 
during early postnatal CNS maturation, after which time it remains fixed for life. These 
studies challenge the notion of DYT1 dystonia as a “normal structure-abnormal function” 
disease, and highlight a need for careful assessment of postmortem brain tissue from 
DYT1 subjects for cell loss. These mice also provide valuable new model systems for 
studying the pathophysiology of dystonic movements, and for furthering understanding 
of the factors that render discrete cell types vulnerable to torsinA dysfunction.  
DYT6 DYSTONIA 
Etiology and Epidemiology 
DYT6 dystonia was initially termed “idiopathic torsion dystonia of ‘mixed’ type,” 
highlighting the clinical phenotype of upper limb, cervical, and/or cranial involvement 
(Almasy et al., 1997). This dominantly inherited dystonia includes both early and late 
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onset cases, but generally presents during late adolescence with an average age at disease 
onset of ~16 years of age (Fuchs et al., 2009). Linkage analysis of two large Amish-
Mennonite families identified a disease locus on chromosome 8p21-22. A frameshift 
mutation (F45fs73X) was discovered subsequently within the second exon of the gene 
THAP1 (Fuchs et al., 2009). This mutation, found in three Amish-Mennonite families, 
causes a premature stop codon. Genealogic analysis determined the frameshift mutation 
as a founder mutation, but a wide variety of other mutations within THAP1 have since 
been discovered, establishing a pathogenic role for THAP1 as a cause of dystonia in a 
range of ethnic groups (Djarmati et al., 2009; Bressman et al., 2009). THAP1 pathogenic 
mutations have been identified in 13 different ethnicities, and include missense, indels, 
and gene truncation mutations (Blanchard et al., 2011). Like other inherited primary 
dystonias (e.g., DYT1), mutations in THAP1 show reduced penetrance. The current 
estimate of ~60% penetrance is based on data solely from the Amish-Mennonite 
population (Saunders-Pullman et al., 2007). Additional data is needed to determine the 
penetrance of THAP1 mutations in different genetic backgrounds, but this question will 
be complicated by the large number of THAP1 mutations linked to DYT6 dystonia 
(http://www.umd.be/THAP1/) (Blanchard et al., 2011). 
Clinical presentation 
The mean age at onset of DYT6 dystonia (18.1 years) falls between the early age of 
DYT1 (~ 13 years) and adult-onset DYT25 dystonia (~30 years). Of the cohorts studied, 
initial symptoms may be localized to a limb or the cranial region (Bressman et al., 2009; 
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Houlden et al., 2010; Almasy et al., 1997). Disease progression is variable and can 
continue throughout life; many subjects develop generalized dystonia. Symptoms vary 
and can manifest within cranial (facial, lingual, masticatory, blepharospasm, dysathria) 
cervical, truncal, and limbs (LeDoux et al., 2012). DYT6 subjects typically have speech 
impairment, whereas lower limb involvement is less common.  
DTI imaging of DYT6 subjects shows microstructural abnormalities of white matter 
similar to DYT1 subjects (Cheng et al., 2012; Carbon et al., 2010). Additional work is 
required to determine if these phenomena contribute to dystonic movements, or are 
compensatory changes. Decreased D2 receptor availability in the caudate putamen was 
observed in DYT6 mutation carriers, but did not correlate with disease penetrance 
(Carbon et al., 2009).  
Pathogenesis 
The protein encoded by THAP1 is a transcription factor called THAP1 (thanato-
associated protein domain containing apoptosis associated protein 1) (Roussigne et al., 
2003). In addition to the THAP domain, THAP1 contains a low complexity proline rich 
region, a coiled-coil domain, and a nuclear localization signal (NLS). The small three 
exon gene was first recognized for its involvement in regulating genes linked to 
endothelial cell proliferation and cell cycle progression (Cayrol et al., 2007; Clouaire et 
al., 2005). 
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A key question for genetic disease is determining whether pathogenic mutations act 
through a gain- or loss-of-function effect. Essentially all data currently available indicate 
that pathogenic mutations impair THAP1 function, potentially through distinct 
mechanisms. The THAP domain is an atypical zinc-finger DNA-binding domain 
(Bessiere et al., 2008; Campagne et al., 2010). Several DYT6 mutations impair THAP1 
residues known to be critical for DNA binding (Clouaire et al., 2005; Bessiere et al., 
2008), suggesting that THAP1 loss-of-function and the resultant transcriptional 
dysregulation is the pathogenic mechanism of DYT6 dystonia (Fuchs et al., 2009). Not 
all mutations that fall within this region of THAP1 decrease its affinity for DNA, 
however, and some may even enhance it (Schneider et al., 2011; Lohmann et al., 2012; 
Campagne et al., 2012). Several mutations reduce the already low melting temperature 
for THAP1, indicating these mutations may impair THAP1 function by decreasing its 
half-life–an independent loss-of-function mechanism (Campagne et al., 2012). Like other 
zinc-finger transcription factors, THAP1 homo-dimerization via its coiled-coil domain 
increases its affinity for DNA. Several mutations reduce this homo-oligomerization, 
impairing function (Sengel et al., 2011). Moreover, other mutations impair the ability of 
THAP1 to localize to the nucleus, thereby preventing it from interacting with DNA 
(Lohmann et al., 2012; Cheng et al., 2012; Sengel et al., 2011). A picture is therefore 
emerging in which pathogenic mutations impair THAP1 function in a variety of ways–
either disrupting dimerization or nuclear localization–possibly leading to a common 
downstream effect of transcriptional dysregulation. Interestingly, one of THAP1’s 
transcriptional targets is itself (Erogullari et al., 2014). While in vitro studies identify the 
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DYT1 gene TOR1A, as a THAP1 target (Gavarini et al., 2010; Kaiser et al., 2010), levels 
of torsinA mRNA and protein are normal in DYT6 patient fibroblasts (Kaiser et al., 
2010), arguing against a mechanistic link between these proteins.  
DYT5 DYSTONIA – DOPAMINE-RESPONSIVE DYSTONIA 
Etiology and Epidemiology 
Dominant mutations in GCH1 cause DYT5 dystonia, known variously as Segawa's 
disease, dopamine-responsive dystonia (DRD), and hereditary progressive dystonia. 
Since discovery of the original mutations (Ichinose et al., 1994), more than 100 different 
pathogenic mutations have been identified. GCH1 (14q22.2) encodes GTP 
cyclohydrolase 1, which catalyzes the rate-limiting step for the synthesis of 
tetrahydrobiopterin (BH4) synthesis (Nichol et al., 1985), a cofactor essential for normal 
dopamine and serotonin neurotransmission (detailed below in the Pathogenesis section, 
Figure I.2). Mutations are throughout the GCH1 coding and the 5’ promoter regions 
(Theuns et al., 2012; Trender-Gerhard et al., 2009). Several types of mutations have been 
described, including missense, nonsense, indels, splice-site and frameshift mutations, as 
well as copy number variants (Hahn et al., 2001; Theuns et al., 2012). These mutations 
are found throughout the world without apparent predilection for particular ethnic 
backgrounds. Prevalence of the disease is estimated to be 0.5 per million in Europe and 
Japan (Nygaard, 1993).  
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Similar to other inherited dystonias, GCH1 mutations often exhibit reduced penetrance. 
Unique among inherited dystonias, there is a marked 4:1 female predominance, the 
mechanism of which is unexplained (Ichinose et al., 1994; Furukawa et al., 1998). One 
study described a correlation between symptoms and hormonal fluctuations (e.g., 
pregnancy, menstruation, oral contraceptives), but further work is required to define a 
potentially causative role for hormones in disease severity (Trender-Gerhard et al., 2009). 
Clinical presentation 
An extensive description of the DRD clinical phenotype by Dr. Masaya Segawa is 
available in a previous volume of the Handbook of Clinical Neurology (Segawa, 2011). 
Onset during childhood is most common and ranges from 1 to 9 years of age 
(Bruggemann et al., 2014; Trender-Gerhard et al., 2009; Segawa, 2011). Dystonia of the 
feet and legs leading to difficulty walking is the typical clinical presentation. Symptoms 
spread to involve body parts for a decade or more, but typically stabilize during the 3rd 
and 4th decade. Asymmetric lower-limb predominance is frequently reported, though 
symptoms may also spread more widely (Segawa, Nomura, & Nishiyama, 2003; Trender-
Gerhard et al., 2009). Diurnal fluctuation is characteristic, with exacerbation of 
symptoms as the day progresses. Subjects may also exhibit parkinsonism that begins 
concurrently or subsequently to dystonia onset (Trender-Gerhard et al., 2009).  Inter- and 
intra-familial variations in the severity of dystonia or the presence of other signs is 
common, complicating genotype-phenotype relationships (Hahn et al., 2001; Grotzsch et 
al., 2004; Ceravolo et al., 2013). For example, Ceravolo and colleagues describe a 
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pedigree with three affected family members exhibiting unique clinical features: typical 
DRD, adult-onset PD, and a multiple system atrophy-like disorder. Because of the 
potential presence of parkinsonism, DRD is technically a form of secondary and not 
primary dystonia, but we include it here because 1) many cases exhibit isolated dystonia, 
and 2) the importance of DRD highlighting a connection between dopamine and 
dystonia. 
Non-motor symptoms may accompany DRD, including sleep disturbances (Lopez-Laso 
et al., 2011; Van Hove et al., 2006), restless-legs-syndrome (Trender-Gerhard et al., 
2009), deafness (Hahn et al., 2001) and psychiatric problems (Trender-Gerhard et al., 
2009; Lopez-Laso et al., 2011; Hahn et al., 2001; Van Hove et al., 2006). Psychiatric 
diagnoses include anxiety, depression, and obsessive-compulsive disorder. These 
symptoms are hypothesized to result from decreased levels of tryptophan hydroxylase 
and serotonergic dysfunction, but this issue is controversial (Bruggemann et al., 2014). 
Due to the marked heterogeneity of GCH1 mutations, it may be necessary to pursue 
biochemical evidence of reduced GTP cyclohydrolase 1 enzymatic activity for diagnosis. 
A comprehensive discussion of the metabolites used for diagnosis of DRD is beyond the 
scope of this review, we direct the reader instead to the review by Blau and colleagues 
(Blau et al., 2001). Briefly, cerebrospinal fluid (CSF) can be used to measure the levels of 
the metabolites dopamine (homovanillic acid, HVA), serotonin (5-hydroxyindoleacetic 
acid, 5-HIAA), norepinephrine (3-methoxy-4-hydroxy phenylethylene glycol, MHPG), 
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and tetrahydrobiopterin (neopterin and biopterin). GTP cyclohydrolase deficiency, being 
“upstream” of these neurochemicals, typically leads to decreases in some of these 
metabolites (Jeon et al., 1998; Ouvrier, 1978; Furukawa et al., 1993). Interestingly, even 
asymptomatic carriers exhibit moderate reductions in CSF-derived neopterin and 
biopterin (Ichinose et al., 1994; Takahashi et al., 1994).  
DRD must be distinguished from other childhood neurological disorders, including 
several recessively-inherited conditions affecting genes encoding enzymes in the same 
biochemical pathway as GTP cyclohydrolase 1. Recessive deficiencies of 
tetrahydropterin synthase, dihydropterin reductase, sepiapterin reductase, and in GCH1 
itself (causing hyperphenylalaninemia) may also present with dystonia-like symptoms 
due to BH4 deficiency. These patients typically have numerous symptoms in addition to 
dystonia, however, and will not improve following L-DOPA treatment alone; they may 
require BH4 or 5-hydroxytryptophan replacement therapy (Nomura et al., 1998). Subjects 
with BH4 deficiency, for example, exhibit a profound neurological syndrome that includes 
severe mental retardation, hypotonia, convulsions, and hyperthermia.  Similarly, recessive 
mutations in the TH gene encoding tyrosine hydroxylase (Willemsen et al., 2010) cause a 
complex neonatal or infantile-onset of neurologic problems featuring a mixture of 
encephalopathy, dystonia, and parkinsonism.  
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Pathogenesis 
Unlike other monogenic forms of dystonia, the function of the pathogenic protein is well 
defined. GTP cyclohydrolase 1 catalyzes the rate-limiting step of tetrahydrobiopterin 
(BH4) biosynthesis (Nichol et al., 1985). BH4 is a cofactor for tyrosine, tryptophan, and 
phenylalanine hydroxylases, so is required for normal production serotonin and dopamine 
(Kaufman & Levenberg, 1959; Lovenberg et al., 1967; Nagatsu et al., 1964). Without full 
activity of tyrosine hydroxylase, the nigrostriatal dopaminergic system is depleted of 
dopamine, causing inefficient neurotransmission and motor dysfunction. Disease onset 
during childhood emphasizes a specific role for these neurotransmitters during normal 
development of the motor system. The fact that dopamine deficiency during development 
manifests as dystonia as opposed to parkinsonism implies that the developing brain is 
particularly susceptible to dystonia. Similarly, most genetic forms of primary dystonia 
begin during childhood, and dystonia may develop in childhood years following static 
encephalopathy (Burke et al., 1980; Scott & Jankovic, 1996). 
Several groups have examined dopaminergic transmission in DRD using positron 
emission tomography (PET) (Kishore et al., 1998; Künig et al., 1998; Segawa et al., 
2003; Snow et al., 1993; Turjanski et al., 1993). Increased D2-receptor binding was 
observed in both manifesting and non-manifesting carrier states indicating this change is 
not clearly linked to disease symptoms (Kishore et al., 1998). In addition to PET studies 
that suggest an intact nigrostriatal system (Segawa et al., 2003), post-mortem analysis 
and DAT-imaging depict a grossly normal nigrostriatal circuit indicating DRD does not 
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result from any obvious degeneration (Jeon et al., 1998; Rajput et al., 1994). 
Nevertheless, while it is clear that deficient dopaminergic neurotransmission during CNS 
development and maturation cause dystonia, there remains little understanding of the 
circuit mechanisms through which this occurs, or the differences between the young and 
aged basal ganglia that dictate the different responses to dopamine deficiency at these 
different ages.  
DYT25 DYSTONIA (GNAL) 
Etiology and Epidemiology 
The first hints that GNAL, (gene encoding guanine nucleotide binding protein, alpha 
activating activity polypeptide, olfactory type (Gα(olf)), could be a causative gene for 
primary dystonia came from clinical descriptions of patients with 18p- syndrome (Awaad 
et al., 1999; Nasir et al., 2006; Tezzon et al., 1998; Klein et al., 1999). The entire short 
arm of chromosome 18–where GNAL resides–is lost in these patients, who exhibit growth 
retardation, skeletal dysmorphology, severe cognitive dysfunction, and in some subjects, 
dystonia. Exome sequencing identified autosomal dominant GNAL mutations in DYT25 
primary dystonia subjects (Fuchs et al., 2013; Kumar et al., 2014; Vemula et al., 2013). 
To date, ~14 mutations have been identified and are present in many ethnic backgrounds 
including Caucasian (Fuchs et al., 2013; Kumar et al., 2014; Vemula et al., 2013), African 
American (Vemula et al., 2013), Asian (Kumar et al., 2014; Vemula et al., 2013; Miao et 
al., 2013), and Serbian (Dobricic et al., 2014). The sequence variants identified vary 
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greatly to include in-frame deletions, frameshifts, missense, nonsense, splice site 
mutations, and variants that are predicted to result in nonsense mediated decay. Mutation 
analysis programs (e.g. Polymorphism Phenotyping v2 (PolyPhen2), Sorting Intolerant 
From Tolerant (SIFT), and Mutation Taster) are being used to examine in silico the 
potential pathogenicity of GNAL variants (Dobricic et al., 2014; Fuchs et al., 2013; 
Vemula et al., 2013; Ziegan et al., 2014; Zech et al., 2014; Kumar et al., 2014; 
Charlesworth et al., 2014). Concordance between all three programs and the absence of 
the variant in ethnically matched control groups is an indicator of likely pathogenicity of 
newly identified variants. Although infrequent, GNAL mutations fill a critical lack of 
insight on the genetic basis for adult-onset focal dystonia (Charlesworth et al., 2014; 
Zech et al., 2014). 
An alternate first exon for GNAL is conserved from mouse to human, encodes a βγ 
subunit-binding domain, and  results in a larger protein, XLGα(olf) (Corradi et al., 2005). 
While Gα(olf) is primarily expressed in the caudate, putamen, and nucleus accumbens 
(Belluscio et al., 1998), XLGα(olf) is mainly found in the hypothalamus, substantia nigra, 
and spinal cord. Whether dystonia symptoms arise from dysfunctional XLGα(olf), 
Gα(olf), or both, remains to be determined. The presence of CpG islands flanking the 
alternative first exon for GNAL introduces the possibility of genomic imprinting (Corradi 
et al., 2005), however parent-of-origin has not yet been shown to influence symptom 
penetrance (Fuchs et al., 2013). Nevertheless, the characteristics of this loci strengthen 
the idea that this gene has increased susceptibility to genetic alterations (Corradi et al., 
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2005). This is further illustrated by the identification of a de novo mutation in one 
Serbian individual with typical DYT25 clinical attributes (Dobricic et al., 2014). 
Clinical presentation 
The first report identifying GNAL as the DYT25 gene included 28 dystonia patients from 
8 families. Mean age at onset was 31.3 years, however a wide range of 7-54 years of age 
was reported (Fuchs et al., 2013). Incomplete penetrance has been noted in family 
studies, but unaffected individuals had a mean age of 29 suggesting some may go on to 
develop DYT25 dystonia at an adult age (Vemula et al., 2013). This is a predominantly 
craniocervical form of dystonia with symptom onset typically in the neck. The majority 
of affected individuals had disease progression to other muscle groups. Speech 
involvement was commonly reported, but not brachial dystonia distinguishing them from 
DYT6 patients. Since this first cohort was described, additional DYT25 patients have 
been reported. These cases show a similar clinical phenotype, but in some instances 
progress to generalized disease (Miao et al., 2013; Vemula et al., 2013). There is not yet 
commercially available testing for GNAL mutations, nor any unique therapeutic strategy 
for treating GNAL mutant subjects. Testing for this mutation is therefore limited to a 
research setting, including subjects with a positive family history for the purposes of 
counseling.  
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Pathogenesis 
Gα(olf) is a GTP-binding heterotrimeric protein (αβγ) that couples membrane-bound 
receptors to downstream effectors. Originally named for its role in the olfactory 
epithelium where it mediates odorant signaling (Jones & Reed, 1989), Gα(olf) replaces 
Gα(s), the predominant Gα subunit in the brain, striatal medium spiny neurons and 
cholinergic interneurons. Within these cells Gα(olf) appears to participate in mediating 
D1 signaling in the direct pathway and adenosine receptor signaling in the indirect 
pathway (detailed below). While much remains to be learned, this discovery may be the 
first direct link between dopaminergic dysregulation and the pathogenesis of primary 
dystonia. Gα(olf) is expressed in postsynaptic (e.g., “dopaminoceptive”) neurons, so 
DYT25 is not likely to improve with L-DOPA therapy. 
Gα(olf) shares 80% sequence identity with Gα(s) (Jones & Reed, 1989) and therefore is 
predicted to have a Ras-like GTP binding domain and a helical domain that provides 
stability to the GTP binding interface (Fuchs et al., 2013). Three truncation mutations 
(Arg21*, Ser95fs*110, Arg98fs*210) eliminate these functional domains likely producing 
a loss-of-function phenotype. Similarly, the complete loss of GNAL in 18p-syndrome 
patients, who develop dystonic symptoms, supports the notion that DYT25 dystonia is 
likely due to the loss of Gα(olf) function. Bioluminescence resonance energy transfer 
(BRET) assays used to analyze the effects of additional GNAL mutations (Fuchs et al., 
2013; Kumar et al., 2014) provide further evidence for a loss-of-function disease 
mechanism.  
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Analyses of mice mutant for Gα(olf) have provided insight into the role of this protein on 
neurotransmission. Germline Gα(olf) knockout mice exhibit perinatal lethality, likely due 
to an inability to suckle (Belluscio et al., 1998). The small percentage of knockout mice 
that survive to adulthood display hyperactivity, consistent with abnormalities of striatal 
function. Consistent with this notion, heterozygote mice (GNAL+/-) exhibit impaired 
Gα(olf)/cAMP/PKA-dependent phosphorylation in striatal medium spiny neurons 
following treatment with D1 agonists (Alcacer et al., 2012). Abnormalities of D1 
signaling are also implicated in levodopa-induced dyskinesias (LID) in PD, and Gα(olf) 
has also been implicated in this phenomenon. Gα(olf) is up-regulated following 
dopaminergic lesions in rats (Herve et al., 1993; Marcotte et al., 1994; Penit-Soria et al., 
1997; Rangel-Barajas et al., 2011) and humans (Corvol et al., 2004). Although L-DOPA 
therapy initially normalizes Gα(olf) levels, longterm L-DOPA treatment is reported to 
reverse this effect and result in up-regulated Gα(olf) levels (Alcacer et al., 2012; Corvol 
et al., 2004). A correlation between mice with persistent increases in Gα(olf) and LID 
incidence is also reported (Alcacer et al., 2012). These results are complicated by the fact 
that GNAL+/-  mice still develop LID.  
Looking Forward 
Discovery of genetic causes of primary dystonia represents a major advance for the field, 
focusing investigators on specific molecular pathways and opening the possibility of 
modeling dystonia circuitry in a variety of model organisms. We have focused on four 
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autosomal dominant forms of monogenic dystonia, but the mutations causing several 
other forms of the disease have been identified, as reviewed elsewhere (Klein, 2014). The 
effects of dystonia-causing mutations are beginning to be unraveled, and specific 
circuitry responsible for dystonic movement is starting to come into focus. While this 
work has not yet changed clinical practice, it is beginning to suggest novel therapeutic 
approaches, and is a far cry from the not too distant past when many subjects with 
dystonia were believed to be suffering from a psychogenic movement disorder. In the 
coming years, it will be important to continue to search for pathophysiological themes 
that might be common to multiple forms of dystonia, to focus efforts toward developing a 
novel therapeutic strategy that will benefit patients suffering with dystonia. 
Research Objectives 
The primary goal of my dissertation was to characterize a novel conditional knock-in 
mouse model of the DYT1 Dystonia mutation (∆E-Tor1a). The unique genetic strategy 
employed by this mouse line provides the ability to express the disease mutation in an 
anatomical- and temporal-specific manner using Cre recombinase. In Chapter II of my 
dissertation, I describe the extensive characterization of this new mouse model. I 
demonstrate that ∆E-torsinA behaves as expected in these mice by showing the cardinal 
phenotypes observed in past studies (perinuclear staining of ∆E-torsinA, decreased 
steady-state, and NE budding). In addition, I used this mouse line to address two 
important questions in the field. First, I evaluated the gain-of-function (GOF) and loss-of-
function (LOF) properties of the ∆E-Tor1a allele in vivo. Secondly, I asked whether 
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reduced penetrance of DYT1 dystonia is explained by cerebellar dysfunction. To test this 
hypothesis, I expressed the DYT1 genotype specifically in the hindbrain. The usefulness 
of this mouse line is not limited to these two biological questions. In Chapter IV, I discuss 
the potential for this mouse model in exploring questions important to the field of torsin 
biology and primary dystonia. 
Chapter III addresses an in vitro model I developed during my dissertation. I 
recapitulated phenotypes observed in conditional Tor1a LOF mouse models in vitro by 
culturing primary cortical neurons from disease-manifesting mice. This work provides a 
platform to explore the cellular consequences of Tor1a LOF. In addition, this cell culture 
system allowed me to identify a distinct cortical subtype that is specifically vulnerable to 
the loss of torsinA function during neurodevelopment.  
In Chapter IV, I summarize the main contributions of my work to the field of torsin 
biology and DYT1 dystonia. I discuss some of the unanswered questions in the field and 
how the conditional knock-in mouse model and in vitro model can be utilized to address 
these questions. 
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Figure I.1 Monogenic Forms of Primary Dystonia 
Summary of clinical, molecular, and genetic attributes of primary dystonias described in 
Chapter I. AD, Autosomal dominant. D1R, Dopamine Type 1 Receptor. A2A, Adenosine 
Receptor.  
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Figure I.2 Monoamine Neurotransmitter Biosynthesis Pathway 
Illustration of the role DYT5-disease gene GCH1 plays in monoamine neurotransmitter 
biosynthesis. GCH1 encodes GTP cyclohydrolase 1. This enzyme catalyzes the rate-
limiting step in tetrahydrobiopterin (BH4) synthesis, a cofactor essential for normal 
dopamine and serotonin neurotransmission. TRP, tryptophan. PHE, phenylalanine. TYR, 
tyrosine. TPH, tryptophan hydroxylase. PAH, phenylalanine hydroxylase. TH, tyrosine 
hydroxylase. 5HTP, 5-OH-tryptophan. LDOPA, L-3,4-dihydroxyphenylalanine. Italicized 
names indicate enzymes. Dashed arrows indicate indirect pathways.  
!28
 2
CHAPTER II 
A novel conditional knock-in approach defines molecular and circuit effects of the 
DYT1 dystonia mutation 
Abstract 
DYT1 dystonia, the most common inherited form of primary dystonia, is a 
neurodevelopmental disease caused by a dominant mutation in TOR1A. This mutation 
(“∆E”) removes a single glutamic acid from the encoded protein, torsinA. The effects of 
this mutation, at the molecular and circuit level, and the reasons for its 
neurodevelopmental onset, remain incompletely understood. To uniquely address key 
questions of disease pathogenesis, we generated a conditional Tor1a knock-in allele that 
is converted from wild type to DYT1 mutant (“induced” ∆E: Tor1ai-∆E ) following Cre 
recombination. We used this model to perform a gene dosage study exploring the effects 
of the ∆E mutation at the molecular, neuropathological and organismal levels. These 
analyses demonstrated that ∆E-torsinA is a hypomorphic allele, and showed no evidence 
for any gain-of-function toxic properties. The unique capabilities of this model also 
enabled to us test a circuit level hypothesis of DYT1 dystonia which predicts that 
 This chapter was submitted to the journal Human Molecular Genetics for publication on June 2
30, 2015: Weisheit CE, Dauer WT. A novel conditional knock-in approach defines molecular and 
circuit effects of the DYT1 dystonia mutation.
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expression of the DYT1 genotype (Tor1a∆E/+) selectively within hindbrain structures will 
produce an overtly dystonic animal. In contrast to this prediction, we find no effect of this 
anatomic-specific expression of the DYT1 genotype, a finding that has important 
implications for the interpretation of the human and mouse diffusion tensor imaging 
studies upon which it is based. These studies advance understanding of the molecular 
effects of the ∆E mutation, challenge current concepts of the circuit dysfunction that 
characterize the disease, and establish a powerful tool that will be valuable for future 
studies of disease pathophysiology. 
Introduction 
Dystonia is a prolonged abnormal involuntary movement that typically causes twisting or 
abnormal postures. Current treatments are empiric and only partially effective, and our 
limited knowledge of disease pathogenesis and pathophysiology have slowed the 
development of targeted therapies. While dystonia often results from neuronal injury or 
disease in the context of additional neurological symptoms (“secondary” dystonia), 
several inherited forms cause isolated dystonia without associated neurological findings 
(“primary” dystonia). Studies of genetic forms of primary dystonia have advanced 
understanding of dystonia biology because of the experimental power of mouse genetics, 
and ability to link molecular defects, cellular and circuit dysfunction, and neurological 
phenotypes with abnormal behaviors.  
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The most common form of inherited primary dystonia, DYT1, is caused by an in-frame 
3-bp deletion within exon 5 of the gene TOR1A (OMIM: 605204) (Ozelius et al., 1997). 
This mutation (“∆E”) results in the loss of a single glutamic acid from the encoded 
protein torsinA. One effect of the ∆E mutation is to impair normal torsinA function. 
Germline homozygous knock-in mice (Tor1a∆E/∆E) phenocopy the lethality and nuclear 
envelope abnormalities of Tor1a null mice (Goodchild et al., 2005). ∆E-torsinA retains 
some function, however, as isolated CNS expression of this allele (Nestin Cre+ Tor1aFLX/
︎∆E) rescues the early postnatal lethality observed when Tor1a is deleted from the CNS 
(Nestin Cre+ Tor1aFLX/FLX) (Liang et al., 2014). Consistent with these findings, 
biochemical studies indicate that the torsinA-interacting proteins LAP1 and LULL1 
(Zhao et al., 2013; Sosa et al., 2014) are essential for the torsinA ATPase activity, but 
only very weakly activate the mutant protein, ∆E-torsinA.  
Mutation gain- and loss-of function (GOF; LOF) effects are not mutually exclusive (Sun 
et al., 2015; Fakhouri et al., 2014). Several features of DYT1 dystonia and torsinA 
biology are consistent with ∆E-mediated GOF effects. DYT1 dystonia is dominantly 
inherited and the ∆E mutation is the only clearly identified pathogenic mutation–a 
scenario typical of GOF mutations. Re-localization of torsinA from the endoplasmic 
reticulum to the nuclear membrane is an effect of the ∆E mutation, that depends on the 
association with the protein SUN1 (Jungwirth et al., 2011). ∆E-torsinA is found within 
perinuclear inclusions in vitro and similar inclusions have been reported in DYT1 subject 
post-mortem tissue (McNaught et al., 2004). Determining whether these molecular 
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features of ∆E-torsinA contribute to adverse effects in vivo (e.g., for neurological function 
or histopathology) is critical for conceptualizing novel therapeutics, as GOF and LOF 
effects would necessitate distinct approaches. 
Defining the anatomic circuits disrupted by ∆E-torsinA is also critical for future 
development of therapies, as it would help focus efforts on key brain regions or cell 
types. While several lines of evidence implicate the striatum as the major site of 
dysfunction in dystonia (reviewed in (Pappas et al., 2014; Pappas et al., 2015)), an 
emerging literature suggests that the cerebellum is also an important region, and aberrant 
communication between cerebellum and forebrain structures is implicated in disease 
pathogenesis (Chen et al., 2014; Prudente et al., 2014; Raike et al., 2013; Raike et al., 
2015). Only 30% of DYT1 mutation carriers develop dystonic symptoms. Diffusion 
tensor imaging (DTI) MRI studies comparing “manifesting” and “non-manifesting” 
DYT1 mutation carriers show that both subject groups exhibit cerebellothalamic white 
matter tract abnormalities (Carbon et al., 2004; Argyelan et al., 2009). Only non-
manifesting carriers have an additional thalamocortical tract defect, and this “second hit” 
is hypothesized to block the effect of the cerebellothalamic lesion (Argyelan et al., 2009). 
Germline Tor1a∆E/+ mice that mimic the human DYT1 genotype do not develop abnormal 
twisting movements and exhibit the “non-manifesting" carrier DTI signature (Ulug et al., 
2011). These findings predict that selective hindbrain expression of the DYT1 genotype 
at endogenous levels would produce an overtly dystonic model, but the mouse genetic 
reagents necessary to test this prediction do not exist.   
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To address these molecular and circuit-level questions of disease pathogenesis, we 
generated a novel line of conditional DYT1 knock-in mice that allowed us to pursue a 
series of in vivo studies not possible with existing models. These mice express wild type 
torsinA until “induction” by Cre recombination, which swaps out a floxed wild type 
Tor1a exon 5, and brings a previously silent downstream ∆E-containing exon 5 into 
frame. This mutant allowed us to pursue a gene dosage study in vivo to rigorously test for 
organismal GOF effects of ∆E-torsinA. We hypothesized that if the ∆E mutation 
conferred meaningful GOF toxic effects, more severe or novel phenotypes would emerge 
as the number of ∆E-Tor1a knock-in alleles increased. Conversely, increasing levels of a 
solely hypomorphic (LOF) torsinA molecule might, paradoxically, ameliorate ∆E-
torsinA-mediated phenotypes. Analyses of the growth, behavioral and histopathological 
characteristics of these mice demonstrated that increased dosage of the ∆E-Tor1a allele 
suppressed ∆E-torsinA-mediated phenotypes, suggesting that the ∆E mutation exerts an 
exclusive LOF effect. These mice also enabled us to test the pathophysiological 
importance of expressing the DYT1 genotype selectively within hindbrain structures; 
against predictions of the “two hit” model (Niethammer et al., 2011), these mice did not 
exhibit any overt twisting movements. Considered together, these in vivo studies advance 
knowledge of the molecular and circuit abnormalities underlying primary dystonia, and 
establish a unique genetic tool valuable for future studies of dystonia pathogenesis and 
pathophysiology.  
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Results 
A unique line of conditional DYT1 knock-in mice recapitulates molecular and 
ultrastructural features of ∆E-torsinA 
To establish a model enabling the expression of ∆E-torsinA at endogenous levels in an 
anatomical- and temporal-specific manner, we constructed a conditional Tor1a allele that 
is converted from a wild type to a DYT1 mutant allele when acted upon by Cre 
recombinase. In this “Swap allele (Tor1aSwap),” the final exon is flanked by LoxP sites, 
and is followed by a downstream copy of the same exon harboring the ∆E mutation (an 
in-frame GAG deletion that removes a single glutamic acid, E; Figure II.1A). 
Importantly, the endogenous stop codon (TGA) located in the floxed exon 5 ensures that 
in the absence of Cre, Tor1aSwap/Swap mice (Figure II.1E-F) express normal levels of wild 
type torsinA protein (data not shown). To test the predicted Cre inducibility of this model, 
we crossed mice expressing the “gene targeted construct allele” (Figure II.1A) with 
germline-expressing Hprt-Cre mice (Tang et al., 2002). As expected, progeny from this 
cross contain the “induced” Tor1ai-∆E/+ genotype in all tissues. We then intercrossed these 
Tor1ai-∆E/+ mice to obtain Tor1ai-∆E/i-∆E animals. Similar to originally reported Tor1a∆E/+ 
knock-in lines (Goodchild et al., 2005; Dang et al., 2005), this intercross yielded all 
genotypes at the expected Mendelian frequency, a finding confirmed by direct sequencing 
(Figure II.1C). As expected Tor1ai-∆E/+ mice were indistinguishable from littermate 
controls. Similar to previously reported germline homozygous knock-in animals, Tor1ai-
∆E/i-∆E pups failed to nurse and perished within 24 hours of birth (Goodchild et al., 2005; 
Dang et al., 2005). 
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We next examined whether our novel germline Tor1ai-∆E/i-∆E mice exhibit the molecular 
and morphological features of established Tor1a∆E/∆E models (Goodchild et al., 2005). 
Similar to Tor1a∆E/∆E mice (and DYT1 subjects), Tor1ai-∆E/i-∆E mutants show decreased 
steady state levels of ∆E-torsinA, which abnormally concentrates in a perinuclear pattern 
(Figure II.1D-E). Analysis of Nissl stained brains showed that at birth, brain structure was 
grossly normal, as reported for Tor1a∆E/∆E mutants (Figure II.1F). TorsinA null and 
germline Tor1a∆E/∆E mice exhibit characteristic neuronal nuclear envelope abnormalities 
(NE buds) (Goodchild et al., 2005), which were also observed in Tor1ai-∆E/i-∆E neurons 
(Figure II.1G). Considered together, these data confirm that the genetic strategy functions 
as designed, and that Cre-mediated induction of Tor1ai-∆E recapitulates all major 
phenotypic features of the previously reported Tor1a∆E allele.  
Increased Tor1ai-∆E gene dosage suppresses growth deficiency  
To begin to evaluate ∆E-torsinA for toxic GOF effects in vivo, we utilized the Nestin Cre 
transgene to generate a cohort of mice that conditionally express one or two DYT1 
mutant alleles in the CNS. To generate this cohort, we utilized a cross that employed the 
Tor1aSwap and previously reported floxed Tor1a allele (Tor1aFLX; Figure II.8) (Liang et al., 
2014). Crossing Nestin Cre+ Tor1aSwap/+ and Cre- Tor1aSwap/FLX mice allowed us to 
collect all experimental and control mice from the same litters (Figure II.2A). For Figures 
II.2 – II.5, mouse genotypes are labeled using the status of Tor1a in the CNS (see Figure 
II.2A for key). The experimental mice were those expressing either one (Tor1ai-∆E/-) or 
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two (Tor1ai-∆E/i-∆E) DYT1 mutant alleles in the CNS; other genotypes were controls. All 
genotypes were born at the expected Mendelian frequency (Chi squared value = 9.905; df 
= 7). TorsinA protein levels corresponded to the gene dosage of the Tor1a alleles (Figure 
II.2B). 
For all subsequent analyses, we used 4 genotypes as controls (Cre+ and Cre negative 
versions of Tor1aFLX/+ and Tor1aSwap/+), discarding Cre negative Tor1aSwap/Swap and Cre 
negative Tor1aSwap/FLX mice. No significant differences in birth weight were observed 
between the different genotypes. Survival of both experimental groups (Tor1ai-∆E/- and 
Tor1ai-∆E/i-∆E) was significantly reduced compared to controls (Log-rank Mantel-Cox test; 
P value = 0.0017, post-hoc analysis Fisher’s Exact test; Tor1ai-∆E/- vs. controls: P value < 
0.0001 and Tor1ai-∆E/i-∆E vs controls: P value = 0.0492) (Figure II.2C). The survival rate 
for mice expressing one Tor1ai-∆E allele (Tor1ai-∆E/-) was 47.37%, and was 73.68% in 
mice containing a second Tor1ai-∆E allele (Tor1ai-∆E/i-∆E). The difference between survival 
curves for Tor1ai-∆E/- and Tor1ai-∆E/i-∆E genotypes was not statistically significant (Fisher’s 
Exact test; P value = 0.1837), demonstrating that increased Tor1ai-∆E gene dosage does 
not significantly impair survival. Assessment of growth demonstrated a significant 
improvement with increased Tor1ai-∆E gene dosage (Figure II.2D). Both experimental 
groups were significantly lighter than control animals (Two-way ANOVA; F5,74 = 50.09, P 
value < 0.0001 and Tukey’s multiple comparison test) and required an extended weaning 
period (Figure II.9). However, this growth defect was significantly suppressed in mice 
containing two Tor1ai-∆E alleles (Tor1ai-∆E/i-∆E, Tukey’s multiple comparison test). Mice 
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that died prior to the final time point of P56 were excluded from growth analysis. 
Significant postnatal lethality in experimental groups means the sickest animals were 
omitted from growth analysis, suggesting our results are a conservative representation. 
These data demonstrate that increasing amounts of ∆E-torsinA–when analyzed in the 
absence of any wild type protein–suppress torsinA LOF-mediated growth deficiency. 
Increased Tor1ai-∆E  gene dosage does not significantly exacerbate motor 
abnormalities 
In the early postnatal period, both experimental groups (Tor1ai-∆E/- and Tor1ai-∆E/i-∆E) 
exhibited delays in neurodevelopmental milestones such as eye opening, and were visibly 
weak and tremulous (Supplemental Video 1). Assessment of motor behavior 
demonstrated that both mutant groups were significantly impaired compared to controls, 
but never differed significantly from each other (Figure II.3). Both experimental groups 
exhibited several abnormal behaviors during tail suspension including forelimb clasping, 
truncal twisting, and sustained forepaw straining (Figure II.3A and Supplemental Video 
2). Assessment of videos of this behavior by an observer blinded to genotype 
demonstrated that both experimental groups differed significantly from controls at P21 
(One-way ANOVA; F5,69 = 28.84 P value < 0.0001 and Tukey’s multiple comparison test, 
*) and P60 (One-way ANOVA; F5,67 = 15.75 P value < 0.0001 and Tukey’s multiple 
comparison test, * ), but not from each other (Figure II.3B). A similar pattern was 
observed in the horizontal grid hang test, which assesses forelimb dexterity, strength, and 
coordination by requiring the mouse to hang upside down from a mesh grid (adapted 
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from (Tillerson & Miller, 2003)). Both experimental groups were significantly impaired 
in their ability to remain suspended from the grid, but did not differ significantly from 
each other at either age tested (P21: One-way ANOVA; F5,76 = 5.817 P value = 0.0001 
and Tukey’s multiple comparison test, * and P60: One-way ANOVA; F5,73 = 8.402 P < 
0.0001 and Tukey’s multiple comparison test, *) (Figure II.3C). Falling was often caused 
by a twisting phenotype as they attempted to traverse the grid (Supplemental Video 3). 
The ability to traverse a balance beam was also used to assess motor function. All mice 
had 3 days of training prior to testing. Control animals displayed no difficulties 
performing this task with their tail and feet remaining above the beam as they crossed 
(Supplemental Video 4). In contrast, both experimental groups displayed a hunched 
posture on the beam and typically crossed the beam using their forepaws, while dragging 
their hindpaws (Figure II.3D). The beam crossing behavior was also assessed by videos 
taken on the last day of testing. There was no significant difference in the time to cross 
the beam, but both experimental genotypes differed from controls by exhibiting abnormal 
truncal postures during the task and displaying significantly more footslips per cross 
(One-way ANOVA; F5,25 = 7.766 P = 0.0002 and Tukey’s multiple comparison test, *). 
Considered together, these analyses assessing Tor1ai-∆E gene dosage do not support a ∆E-
torsinA GOF effect on motor behavior. 
Increased Tor1ai-∆E gene dosage rescues neurodegeneration  
We reported previously that torsinA LOF causes neurodegeneration in distinct 
sensorimotor structures (Liang et al., 2014). Affected regions became gliotic and 
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susceptible neurons within those regions exhibited a distinctive perinuclear accumulation 
of ubiquitin. A single Tor1a∆E allele significantly reduced the magnitude of neuronal loss 
caused by conditional CNS deletion of torsinA (Liang et al., 2014). We took advantage of 
these histopathological features to further examine the effect of ∆E-torsinA on cellular 
phenotypes linked to abnormal twisting behavior. Consistent with this previous work, 
both experimental groups (Tor1ai-∆E/- and Tor1ai-∆E/i-∆E) recapitulated the region-specific 
gliosis and ubiquitin accumulation (Figure II.4). GFAP and ubiquitin 
immunohistochemistry demonstrated discrete abnormal foci in several sensorimotor 
structures in both experimental groups, including in deep cerebellar nuclei (DCN), cortex, 
thalamus, red nucleus and facial motor nucleus (Figure II.4, II.10-II.11). The abnormal 
immunostaining appeared qualitatively similar in both experimental groups. To assess 
neurodegenerative effects of ∆E-torsinA quantitatively, we used unbiased stereology to 
determine the extent of cell loss associated with different dosages of Tor1ai-∆E. We 
performed this analysis on the deep cerebellar nuclei (Figure II.5), a structure for which 
the extent of torsinA dysfunction-related cell loss has been established (Liang et al., 
2014). Analysis of 2 month old experimental (Tor1ai-∆E/- and Tor1ai-∆E/i-∆E) and control 
mice confirmed that, as expected, mice expressing a single Tor1ai-∆E allele show a 
significant reduction in the number of DCN neurons (One-way ANOVA; F2,12 = 4.425 P 
value = 0.0363 and Tukey’s multiple comparisons test) (Figure II.5C). In contrast, mice 
carrying two Tor1ai-∆E alleles (Tor1ai-∆E/i-∆E) did not show a significant loss of DCN 
neurons, demonstrating a protective effect of increased Tor1ai-∆E gene dosage, as 
observed for weight gain (Figure II.2D). These findings are consistent with the 
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conclusion that the ∆E mutation creates a hypomorphic form of torsinA that does not 
exert toxic GOF effects.  
Hindbrain-selective induction of the DYT1 genotype does not cause abnormal 
twisting movements 
Generation of the Tor1aSwap allele also enabled us to test a model of circuit dysfunction 
proposed to explain the reduced penetrance characteristic of the DYT1 mutation. This 
model is based upon diffusion tensor imaging (DTI) studies of human DYT1 subjects 
(Carbon et al., 2004; Argyelan et al., 2009; Trost et al., 2002) and DYT1 knock-in mice 
(Ulug et al., 2011). DTI imaging of DYT1 subjects who manifest dystonia exhibit 
microstructural abnormalities primarily of cerebellothalamic projections, whereas 
unaffected DYT1 mutation carriers and asymptomatic DYT1 knock-in mice (Tor1a∆E/+) 
(Tanabe et al., 2012) exhibit both cerebellothalamic and thalamocortical defects. These 
data suggest that dystonia-related signaling could originate in cerebellothalamic 
projections, and that the thalamocortical abnormality prevents such aberrant signaling 
from reaching forebrain output nuclei. This model predicts that selective induction of the 
DYT1 genotype in hindbrain structures should cause abnormal twisting movements. We 
tested this prediction by crossing Tor1aSwap/+ and engrailed1-Cre (En1 Cre) mice that 
express Cre recombinase in hindbrain structures, including all cerebellar neurons 
(Kimmel et al., 2000). We directly sequenced cerebellar and frontal cortical tissue to 
confirm that En1 Cre converts Tor1aSwap to a Tor1ai-∆E allele selectively in the hindbrain, 
and that forebrain tissue remains unaffected (Figure II.6A; see methods for details on 
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confirming selectivity of Cre action). En1 Cre+ Tor1aSwap/+ (Tor1ai-∆E/+ selectively in 
cerebellum/brainstem) mice were born at the expected Mendelian frequency and were 
indistinguishable from their littermate controls up to 12 months of age. These hindbrain-
specific Tor1ai-∆E/+ mice did not differ from their littermate controls in tail suspension, 
grid hang, or balance beam testing (Figure II.6B). Similarly, these mutants did not differ 
from their littermate controls in histopathological assessments, including Nissl staining 
and immunostaining for GFAP and ubiquitin (Figure II.7).  
Discussion 
We sought to address fundamental questions regarding the effects of the ∆E mutation at 
the molecular and circuit level, and to assess the contribution of these effects to motor 
dysfunction. We pursued these questions by developing a novel genetic strategy that 
enabled us to convert Tor1a from a wild type to a DYT1 mutant allele in an anatomic- 
and temporal-specific manner. Using this powerful approach, we pursued a unique series 
of studies to assess potential gain- and loss-of-function effects of the ∆E mutation. These 
studies demonstrate that the ∆E mutation impairs torsinA function, as all phenotypes 
observed are those tied to torsinA LOF (Liang et al., 2014). None of the phenotypes we 
assessed–survival, growth, motor function, and histopathology–were exacerbated by 
increased Tor1ai-∆E gene dosage. Indeed, increased Tor1ai-∆E gene dosage suppressed the 
extent of neurodegeneration, which is consistent with a strictly LOF effect of the DYT1 
mutation. We also utilized the anatomic-selective capability of our model to explore the 
prediction that hindbrain-specific expression of the DYT1 genotype (Tor1ai-∆E/+) at 
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endogenous levels would cause overtly abnormal behavior, which was refuted by this 
study. These experiments demonstrate the unique power of this conditional knock-in 
model to address essential questions of DYT1 pathogenesis at the molecular and circuit 
levels, and establish a platform for future studies of dystonia pathophysiology. 
We are aware of only four other conditional knock-in models in the scientific literature 
(Wingate et al., 2009; Skvorak et al., 2006; Bayascas et al., 2006; Parra et al., 2014). This 
strategy avoids the pitfalls that accompany transgenic or viral-based methods that over-
express a non-physiological amount of protein. Several of these previous reports utilized 
an approach in which a multi-exon wild type “minigene” is inserted upstream of a knock-
in-containing exon (Wingate et al., 2009; Bayascas et al., 2006; Parra et al., 2014). 
Without cre, the minigene (including stop codon) is transcribed. Following Cre removal 
of this wild type minigene, the mutant knock-in exon (and downstream exons) is utilized. 
Skvorak and colleagues used an approach similar to ours, but they fused the final two 
exons (Skvorak et al., 2006). In contrast, the location of the DYT1 mutation within the 
final Tor1a exon enabled us to avoid the use of a minigene, or fused exons, and leaves the 
endogenous gene entirely intact. The success of our approach is demonstrated by our use 
of the Tor1aSwap allele to recapitulate previously reported behavioral and 
histopathological phenotypes, and to conditionally induce the DYT1 mutant torsinA in an 
anatomically selective manner. Anatomical- and temporal-selective manipulation of 
endogenous levels of ∆E-torsinA will be valuable for future studies dissecting the cellular 
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anatomy of primary dystonia and assessing the role of neural development in disease 
pathogenesis, both of which are poorly understood.  
DYT1 dystonia is dominantly inherited, but mouse models that mimic the human 
genotype fail to recapitulate a manifesting state (Tanabe et al., 2012). The reasons for the 
absence of an overt phenotype in heterozygous mice (Tor1a∆E/+) are unclear, but may 
include differences in the developmental timing or levels of torsinA-pathway molecules 
such as torsinB, LAP1 or LULL1. The conditional knock-in model enabled us to generate 
the first homozygous ∆E-Tor1a model that is viable, which displays overtly abnormal 
motor behavior and dystonia-like movements. The fact that this model recapitulates the 
behavioral and histological phenotypes identified using independent genetic strategies to 
manipulate Tor1a (Liang et al., 2014), further strengthens those findings and the link 
between developmental neurodegeneration of discrete sensorimotor regions and abnormal 
twisting movements. In contrast to that report, we observe significant lethality prior to 
weaning using this conditional knock-in strategy. This difference may reflect the fact that 
in the approach used by Liang and colleagues the Tor1a∆E allele is expressed 
constitutively, allowing compensatory mechanisms to develop prior to the postnatal 
vulnerable period (Liang et al., 2014). 
To date, few studies have probed the mechanism of action of the ∆E mutation in vivo. 
Comparisons between different versions of ∆E knock-in and Tor1a knockout mice 
demonstrate that the ∆E mutation impairs torsinA function and link torsinA hypofunction 
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to abnormal twisting movements (Liang et al., 2014; Zhang et al., 2011; Goodchild et al., 
2005). These studies do not exclude the possibility that the ∆E mutation also exerts 
neomorphic toxic GOF effects (distinct from dominant negative effect, which result in 
LOF). We devised a novel strategy that enabled us to obtain the first viable homozygous 
∆E-Tor1a model, and exploited this model to directly investigate toxic GOF effects. We 
found no evidence for a toxic GOF effect in comparisons of mice harboring one (Nestin 
Cre+ Tor1aSwap/FLX) or two (Nestin Cre+ Tor1aSwap/Swap) ∆E alleles in the CNS, including 
assessments of growth and viability, motor behavior, and histopathology. In fact, 
increasing Tor1ai-∆E gene dosage significantly attenuated some phenotypes (growth and 
neuronal cell number). These results are most consistent with a model in which ∆E exerts 
LOF effects exclusively, and that higher levels of the hypomorphic protein are beneficial 
because they boost the overall amount of torsinA activity. This finding has important 
implications for devising therapeutic approaches for DYT1 dystonia. Our findings do not 
address whether increasing levels of mutant torsinA would be beneficial in DYT1 
subjects, wherein the presence of wild type protein, dominant negative effects of mutant 
torsinA would likely prove harmful.  
The Tor1aSwap allele also allowed us to test a model of DYT1 circuit dysfunction based 
on DTI imaging data from human subjects and a mouse model (Carbon et al., 2004; Ulug 
et al., 2011; Trost et al., 2002). This model predicts that selective hindbrain expression of 
the DYT1 genotype (Tor1a∆E/+) would cause overt abnormal behavior. Our studies are not 
consistent with this prediction, despite the fact that the Cre driver utilized expresses in all 
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cerebellar cell types, including those vulnerable to more marked degrees of torsinA LOF 
(Liang et al., 2014). One potential reason for the difference between the predicted and 
experimental results concerns the interpretation of DTI imaging changes. Rather than 
reflecting lesions per se, DTI changes may represent a functional compensation (Mackey 
et al., 2012) to primary changes that begin elsewhere (e.g., in striatum (Pappas et al., 
2015)). 
Taken together, our findings provide knowledge of the effects of the ∆E mutation at the 
molecular and circuit levels that will be important for future studies of disease 
pathogenesis and therapeutic development. We developed a novel line of Tor1a mutant 
mice that will enable a range of future studies into the mechanisms underlying the unique 
vulnerability of discrete cell types to torsinA LOF and the role of neural development in 
the manifestation of dystonia.  
Materials and Methods 
Animal Husbandry 
Mice were housed in the University of Michigan animal care facilities on a 12 hour light/
dark cycle. Food and water were provided ad libitum. Animal care was in accordance 
with the University Committee on Use and Care of Animals.  
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Mice 
Novel conditional knock-in mice were generated in collaboration with the Gene Targeting 
and Transgenic Facility at UCONN Health. A BAC clone RP337K9 (from Children’s 
Hospital Oakland Research Institute) was used with a recombineering-based method to 
insert the region of interest into plasmid pl253. This modified bluescript plasmid contains 
a negative selection marker for ES targeting. Multi-step PCR was used to create the 
mutated exon 5 (3 base pair deletion ‘GAG’) + 3’ UTR. After sequencing verification, the 
correct product was cloned into the pI253-Tor1a vector downstream of the wild type exon 
5 + 3’ UTR. To establish the “gene targeted construct” (Figure II.1A), a loxp site was 
inserted upstream of the wild type exon 5 and a frt-neomycin-frt-loxp cassette was 
inserted downstream of the wild type exon 5 + 3’ UTR and before the mutated exon 5 + 
3’ UTR. Electroporation of the gene targeted construct into a hybrid B6/129SVEV ES 
line followed by screens using long range PCR allowed for collection of positive clones 
to generate a chimera. To generate the clean “Swap allele” (Figure II.1A), the chimera 
were bred to Flpe-expressing mice to remove neomycin through recombination of Frt 
sites. 
Nestin Cre+ (003771), Hprt Cre+ (004302), and En1 Cre+ (007916) mice were purchased 
from Jackson Laboratory (Bar Harbor, ME, USA). Germline DYT1 knock-in mice 
(Tor1a∆E) were used in this study to verify our new mouse model (Goodchild et al., 
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2005). Mice used to conditionally delete Tor1a (Tor1aFLX) were previously published by 
our lab (Liang et al., 2014). 
Genotyping 
Ear (Postnatal day 17 and older) and tail samples (Postnatal day 0) were digested in 
50mM NaOH for 15 minutes at 95˚C followed by neutralization with 1M Tris HCl 
(Sigma). Resulting DNA was used for genotyping PCR with the necessary primers and 
Taq 2x Master Mix (Empirical Bioscience; TP-MM-1000). All primers were obtained 
from Integrated DNA Technologies (Coralville, IA, USA). Genotyping primers to 
d i s t i n g u i s h To r 1 a + a n d g e r m l i n e To r 1 a i - ∆ E a l l e l e s : L o x p F 5 ’ 
TCCTCCCCCAAGTACATCAG 3’; LoxpR 5’ CGTCCAGTCCTGGAAACACT 3’; FrtR 
5’ TGGAACTGACGACCACTCAG 3’. PCR program 94˚C, 3 min; (94˚C, 30 seconds; 
65˚C, 30 seconds; 72˚C, 30 seconds) X 33 cycles; 72˚C, 5 minutes; 4˚C, 2 minutes. Band 
sizes: 180bp +; 268bp gene targeted construct; 399bp germline i-∆E (Figure II.1B). 
Genotyping primers to detect deletion of neomycin cassette: FrtF 5’ 
GCCTCTGTGCTCTTCTCTGG 3’; FrtR 5’ TGGAACTGACGACCACTCAG 3’. PCR 
program: 94˚C, 3 min; (94˚C, 30 seconds; 69˚C, 30 seconds; 72˚C, 30 seconds) X 33 
cycles; 72˚C, 5 minutes; 4˚C, 2 minutes. Band sizes: 276bp internal positive control; 
374bp (Swap allele) neomycin cassette removed; >2kb (gene targeted construct) 
neomycin cassette included. Other than validation experiments described in Figure II.1, 
all animals used for this study were derived from the Swap allele after neomycin cassette 
deletion.  
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Genotyping primers to distinguish Tor1a+, Tor1aSwap, and Tor1aFLX alleles: LoxgtF 5’ 
CCTGCCTCAGCCTAACTACG 3’; LoxgtR 5’ TGTGTGCATTTACCCAGAGC 3’ ; 
L o x p F 2 5 ’ G G A C A C A T T G G G C C A C C T T G 3 ’ ; L o x p R 5 ’ 
CGTCCAGTCCTGGAAACACT 3’. PCR program: 94˚C, 3 min; (94˚C, 30 seconds; 
65˚C, 30 seconds; 72˚C, 30 seconds) X 33 cycles; 72˚C, 5 minutes; 4˚C, 2 minutes. Band 
sizes: 213bp and 519bp Tor1a+/+; 213bp, 307bp, 519bp Tor1aFLX/+; 213bp, 519bp, 607bp 
Tor1aSwap/+; 307bp, 519bp Tor1aFLX/FLX; 213bp, 307bp, 519bp, 607bp Tor1aSwap/FLX; 
213bp, 607bp Tor1aSwap/Swap (Figure II.8). Genotyping methods to detect a Cre 
recombinase positive genotype and constitutive germline knock-in mice (Tor1a∆E) were 
as previously reported (Goodchild et al., 2005; Liang et al., 2014). 
DNA sequencing 
RNA extraction was performed on whole brain lysates using RNeasy Plus Mini Kit 
(Qiagen; 74134). RNA was converted to cDNA using SMARTTM MMLV Reverse 
Transcriptase (Invitrogen; PT4045-2). To isolate cDNA encompassing the DYT1 
m u t a t i o n , P C R w a s p e r f o r m e d u s i n g f o r w a r d p r i m e r 
5 ’ G C C G T G T C G G T C T T C A A T A A 3 ’ a n d r e v e r s e p r i m e r 
5’ACAGTCTTGCAGCCCTTGTC3’. Bands of 262 and 259 base pairs (3bp deletion; 
appear as identical bands after electrophoresis) were isolated using Wizard SV Gel and 
PCR Clean-up system (Promega; A9281). These samples were sent to the University of 
M i c h i g a n ’ s D N A S e q u e n c i n g C o r e w i t h s e q u e n c i n g p r i m e r 5 ’ 
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GCCGTGTCGGTCTTCAATAA 3’. The sequencing primer is located within exon 4 of 
Tor1a, which ensures sequencing is of cDNA derived from mRNA and not genomic 
DNA. Resulting sequences were analyzed using 4Peaks software (A. Griekspoor and 
Tom Groothuis, mekentosj.com). For confirmation of hindbrain-specific induction by 
En1 Cre, we chose to analyze cDNA from En1 Cre+ Tor1aSwap/FLX mice opposed to En1 
Cre+ Tor1aSwap/+ mice (our experimental genotype) in order to visualize single peaks.  
Western Blot 
Protein Lysates were made by homogenizing whole brain tissue in 500 µL of lysis buffer 
(0.1% SDS, 2.5mM Tris HCl, 1mM EDTA) and Complete Mini Protease Inhibitor 
Cocktail (Roche, 11836170001). Protein concentrations were determined using BCA 
Protein Assay Kit (Thermo Scientific, 23227) and analyzed by NanoDropTM (Thermo 
Scientific; Wilmington, USA). Lysates were diluted in Laemmli sample buffer and 20 µg 
of protein was separated on a 10% Mini-PROTEAN® TGXTM polyacrylamide gel (Bio-
Rad, 456-1033). Western blot transfer onto Immun-Blot PVDF membrane (Bio-Rad, 
1620177) was followed by blocking with 5% non-fat dry milk dissolved in PBS-T 
(0.01M Phosphate Buffered Saline, Sigma, P-3813; 0.1% Tween® 20, Sigma, P9416) for 
1 hour. The membrane was incubated at 4˚C overnight with primary antibodies (torsinA, 
Abcam, ab34540 1:10,000; calnexin, Enzo Life Sciences, SPA-860 1:20,000) diluted in 
PBS-T followed by a 1 hour incubation with anti-rabbit IgG-HRP conjugated secondary 
antibody (Cell Signaling, 7074S 1:10,000) diluted in PBS-T. Developing was performed 
using SuperSignal® West Femto (Thermo Scientific, 34095) for torsinA blots and 
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SuperSignal® West Dura (Thermo Scientific, 34075) for calnexin blots. Blots were 
exposed to GETM Healthcare AmershamTM Hyperfilm ECL (Thermo Fisher Scientific, 
45-001-508). 
Immunohistochemistry 
Animals were transcardially perfused with PB (0.1M Phosphate buffer, Sigma, P7994) 
followed by 4% paraformaldehyde (Sigma, P6148) in PB. Brains were post-fixed 
overnight in this fixative and then cryoprotected in 20% sucrose dissolved in PB. 
Sectioning was performed on a Leica CM3050 S (Leica Biosystems, Buffalo Grove, IL, 
USA) cryostat to collect sections of 50 µm (P0 and P10 brains) and 40 µm (adult ages). 
Sections were permeabilized by washing in PBS-Tx (0.01M PBS; 0.01% TritonTM X-100, 
Fisher Scientific, BP151-500) Sections to be stained using peroxidase/DAB methods 
were incubated with 0.3% hydrogen peroxide (Sigma, H1009) diluted in PBS followed 
by PBS washes. For both immunofluorescence and peroxidase staining, sections were 
blocked with 5% NDS (Normal Donkey Serum, Jackson ImmunoResearch, 017-000-121) 
in PBS-Tx for 1 hour. Overnight incubation with primary antibodies diluted in PBS-Tx/
1.5% NDS (torsinA, Abcam, ab34540 1:100; ubiquitin, Dako, Z0458 1:500; GFAP, Dako, 
Z0443 1:2000) was followed by washes in PBS-Tx and a 1 hour incubation in secondary 
antibody (Alexa Fluor® 555 Donkey Anti-Rabbit IgG, Life Technologies, A-31572 1:500; 
Biotinylated Donkey anti-Rabbit, Jackson ImmunoResearch, 711-065-152). For 
immunofluorescent tissue, ProLong® Gold Antifade Reagent with DAPI (Life 
Technologies, P36935) was used for mounting on Fisherbrand® Superfrost® Plus 
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microscope slides (Fisher Scientific, 12-550-15). Sections to be stained for peroxidase 
activity were incubated with VECTASTAIN Elite ABC kit (Vector Laboratories, 
PK-6100) followed by DAB (SIGMAFASTTM 3,3’-Diaminobenzidine tablets, Sigma, 
D4418). DAB-stained sections were then mounted on slides and dried overnight before 
dehydrating in ethanol and clearing with FisherbrandTM CitrosolvTM Clearing Agent 
(Fisher Scientific, 22-143-975) and cover slipping with Fisher ScientificTM PermountTM 
Mounting Medium (Fisher Scientific, SP15-500). Nissl staining with Cresyl Violet 
Acetate (Sigma, C5042) was performed on unstained sections that were mounted on 
slides followed by cover slipping as described. Imaging was performed on a Axioskop2 
microscope (Carl Zeiss Microscopy, USA) and an Olympus digital camera (model DP70, 
USA). 
Stereology 
Stereological investigations were completed on both mutant genotypes (Nestin Cre+ 
Tor1aSwap/Swap and Nestin Cre+ Tor1aSwap/FLX) and one littermate control (Nestin Cre+ 
Tor1aSwap/+). Five animals were used per genotype. Animals were transcardially perfused 
as described above at two months of age. Prior to cryosectioning, the primary researcher 
was re-blinded to animal genotype and remained blinded until all stereological counts 
were made. Brains were sectioned coronally at 30 µm and Nissl stained. Stereo 
Investigator (MBF Bioscience Williston, VT, USA) software was used to perform 
stereological analysis of neurons within the lateral, interposed, and medial regions of the 
deep cerebellar nuclei. Every third section was counted using a counting frame of 80 µm2 
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and sampling grid of 125 µm2. These parameters allowed for a coefficient of Gunderson 
< 0.1. Counts from individual regions were summed and averaged per genotype to allow 
for comparison of total deep cerebellar nuclei.    
Ultrastructural Analysis 
Postnatal day 0 pups were transcardially perfused with 4% paraformaldehyde/2.5% 
glutaraldehyde (Electron Microscopy Sciences, 15710 and 16220 respectively) in PB. 
Brains were collected and post-fixed for 2 weeks in the same solution. Preparation of 
brains for electron microscopy was performed in collaboration with the Robert P. 
Apkarian Integrated Electron Microscopy Core at Emory University as previously 
described (Goodchild & Dauer, 2005). Imaging was performed at University of 
Michigan’s Microscopy and Image Analysis Laboratory using a Philips CM-100 
transmission electron microscope (Philips, Amsterdam, Netherlands). 
Animal Viability and Growth 
To assess perinatal lethality in our Hprt Cre recombinase induced knock-in Tor1ai-∆E 
mouse model, we generated homozygous mice (Tor1ai-∆E/i-∆E) by intercrossing two mice 
heterozygous for the germline mutation. Litters were genotyped at postnatal day 0 and 
monitored for lethality.  
To compare Nestin Cre+ Tor1aSwap/Swap and Nestin Cre+ Tor1aSwap/FLX born in the same 
litters, we employed the breeding strategy of Nestin Cre+ Tor1aSwap/+ mice mated with 
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Cre- Tor1aSwap/FLX mice. This resulted in 8 possible genotypes as offspring (Figure II.2A). 
The following genotypes were kept for this study: Nestin Cre+ Tor1aSwap/Swap , Nestin Cre
+ Tor1aSwap/FLX , Nestin Cre+ Tor1aSwap/+ , Nestin Cre+ Tor1aFLX/+ , Cre- Tor1aSwap/+ , Cre- 
Tor1aFLX/+. Two genotypes were omitted from this study and sacrificed at postnatal day 0: 
Cre- Tor1aSwap/Swap, Cre- Tor1aSwap/FLX. Breeding cages housing two females and one 
male were used to generate this cohort, and one week prior to giving birth, each female 
was separated into her own cage. This arrangement allowed for accurate data collection, 
prevented overcrowding, and reduced competition for nutrients. To measure survival and 
growth, each pup was weighed and genotyped at postnatal day 0 (birth weight). Date of 
birth was determined to be the day in which pups were observed between 6:00AM - 
12:00PM. Pups included in this study were weighed every other day until 21 days old, 
and then mice were weighed weekly until postnatal day 56. Litters were observed each 
day in order to collect dead animals for survival analysis.  
Motor Behavior 
Mixed housing was used for all mice in this study to eliminate environmental bias. Male 
and female mice were used for analysis of survival, growth, tail suspension and grid hang 
behavior tests. Only males were used for balance beam behavior tests.  
Tail suspension  
Individual mice were held by the tail 20 cm above a table top, and 15-second videos were 
recorded. Abnormal behaviors included: forelimb clasping, truncal twisting, and 
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sustained straining of forepaws. Videos were analyzed by a researcher blinded to 
genotype. Time spent clasping, twisting, and forepaw straining (in seconds) were 
calculated separately and combined to generate an overall severity score. 
Horizontal Grid Hang  
The horizontal grid apparatus was modeled after a previously published grid hang test 
(Tillerson & Miller, 2003). The grid’s measurements are: 21 cm height, 21.5 cm width, 
21.5 cm length. Testing involved placing a mouse in the middle of the grid, followed by 
careful turning of the apparatus and placing it on the table top. This required the mouse to 
hang upside down from the grid mesh. Latency to fall from the grid was measured using 
video recording. A maximum of one minute was filmed for this test.  
Balance Beam  
Mice received 3 consecutive days of training and a fourth testing day. On each day, the 
mouse was placed on an open platform (20 cm2) and allowed to cross a plexiglass beam 
of 44 cm in length at a height of 53 cm to a dark box (20 cm3) three times. On the first 
day a 2 cm wide balance beam was used for the first two crossings followed by a crossing 
on a 1 cm wide beam. The second, third, and fourth (test) days used a bar of 1 cm width. 
For testing, each mouse was filmed as it performed the beam crossing. The videos were 
then analyzed for abnormal postures and crossing behaviors by investigators blinded to 
genotype. Number of footslips per cross was calculated and averaged per animal. Latency 
to cross was measured for each crossing and averaged per animal.  
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Data Analysis 
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was used to 
analyze all data. Means are displayed with error bars representing SEM. All One-way 
ANOVA tests were followed by post-hoc Tukey’s multiple comparison tests. All Kruskal 
Wallis nonparametric tests were followed by post-hoc Dunn’s multiple comparison tests. 
Significance was determined to be a P value < 0.05.  
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Figure II.1  A novel conditional ∆E-Tor1a knock-in model recapitulates key torsinA 
loss-of-function phenotypes.  
(A) Schematic representations of modified Tor1a gene at different stages of development 
(wild type, gene targeted construct, Swap allele, and the induced knock-in “i-∆E” allele). 
Half arrows indicate genotyping primer locations. Expected band sizes are shown. 
Inverted triangle above exon 5 demonstrates the wild type sequence and deletion of 
‘GAG’ from the gene targeted construct. (B) Left, to distinguish each Tor1a allele (Tor1a
+:180bp ; Tor1aSwap: 268bp; Tor1ai-∆E: 399bp). Right, The Swap allele was generated from 
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the original gene targeted construct by using Flpe-expressing mice to remove the 
neomycin cassette. PCR confirms removal of neomycin cassette from Swap allele 
(374bp). (C) Sanger sequencing of cDNA from P0 brains. Double peaks indicate the 
presence of the Tor1a+ and Tor1ai-∆E alleles following Hprt Cre recombinase induction in 
heterozygous animals (Tor1ai-∆E/+). Intercrossing Tor1ai-∆E/+ mice results in offspring with 
a Hprt Cre induced homozygous genotype (Tor1ai-∆E/i-∆E) with single peaks indicating 
deletion of ‘GAG’ nucleotides and loss of a single glutamic acid, E. (D) Western blot 
analysis of P0 mouse brain lysate from Tor1a+/+, Hprt Cre induced mutants (Tor1ai-∆E/+, 
Tor1ai-∆E/i-∆E) and previously published germline knock-in Tor1a∆E mice (Goodchild et 
al., 2005). Calnexin is used as loading control (20 µg loaded in technical duplicates). (E) 
TorsinA immunohistochemistry of P0 brains. Scale bars = 10 µm. This analysis 
demonstrates the expected perinuclear concentration of ∆E-torsinA in Tor1ai-∆E/i-∆E 
sections. (F) Nissl stained saggital sections from P0 animals. (G) Transmission electron 
microscope images of nuclear envelope budding in Tor1ai-∆E/i-∆E P0 brainstem neurons 
demonstrating nuclear membrane buds. Scale bar = 2 µm. N = Nucleus. Inset shows 
higher magnification, scale bar = 500 nm.  
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Figure II.2 Increased Tor1ai-∆E gene dosage suppresses torsinA loss-of-function 
growth deficiency  
(A) Table describing breeding strategy and nomenclature used for gene dosage 
experiments. All  pups were born in the expected Mendelian ratio (Chi squared value = 
9.905; df = 7). (B) Western analysis of P0 brain lysate confirms that torsinA protein levels 
vary with gene dosage. Three biological replicates are shown. Calnexin is used as loading 
control (20 µg loaded / sample). (C) Survival curves for offspring of Nestin Cre+ 
Tor1aSwap/+ X Cre- Tor1aSwap/FLX cross outlined in II.1A. Survival analysis indicates 
significant difference in survival curves, Log-rank Mantel-Cox test; P value = 0.0017. 
Post-hoc analysis demonstrated that Tor1ai-∆E/- and Tor1ai-∆E/i-∆E mice had decreased 
survival compared to controls (Fisher’s Exact test; Tor1ai-∆E/- vs. controls: P value < 
0.0001 and Tor1ai-∆E/i-∆E vs controls: P value = 0.0492), however survival of mutant 
genotypes did not differ from each other (Fisher’s Exact test; P value = 0.1837). (D) 
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Growth curve demonstrates that increased Tor1ai-∆E gene dosage suppresses growth 
deficiency (Two-way ANOVA; F5,74 = 50.09, P value < 0.0001 and Tukey’s multiple 
comparison test). Tor1ai-∆E/i-∆E and Tor1ai-∆E/- mice were significantly smaller than 
littermate controls beginning at P7 (denoted by “+” over graph). Tor1ai-∆E/i-∆E mice were 
significantly heavier than Tor1ai-∆E/- at multiple ages (indicated by *). Mice that died prior 
to P56 were excluded from growth curve analysis.  
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Figure II.3 Increased Tor1ai-∆E  gene dosage does not significantly exacerbate motor 
abnormalities 
(A) Representative photographs showing normal (1) and abnormal (2-4) responses to tail 
suspension testing. (B) Quantification of tail suspension behavior at P21 (One-way 
ANOVA; F5,69 = 28.84 P value < 0.0001 and Tukey’s multiple comparison test, *) and 
P60 (One-way ANOVA; F5,67 = 15.75 P value < 0.0001 and Tukey’s multiple comparison 
test, * ). Experimental mice did not differ from each other at either time point, ns. Means 
± SEM for each genotype are displayed, with N above or within bar graph. (C) 
Quantification of horizontal grid hang behavior at P21 (One-way ANOVA; F5,76 = 5.817 P 
value = 0.0001 and Tukey’s multiple comparison test, *) and P60 (One-way ANOVA; 
F5,73 = 8.402 P < 0.0001 and Tukey’s multiple comparison test, *). Means ± SEM for each 
genotype are displayed, with N above or within bar graph. Experimental mice did not 
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differ from each other at either time point, ns. (D) Quantification of balance beam 
behavior. Representative images of beam crossing (littermate control, Tor1ai-∆E/i-∆E and 
Tor1ai-∆E/- mice). Note hunched posture and gripping of beam by hindlimbs in both 
mutant genotypes. There were no significant differences in average latency to cross the 
beam, but both experimental groups displayed significantly more footslips per cross 
compared to controls (One-way ANOVA; F5,25 = 7.766 P = 0.0002 and Tukey’s multiple 
comparison test, *). Means ± SEM for each genotype are displayed, with N above or 
within bar graph. Experimental mice did not differ from each other, ns. 
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Figure II.4 Conditional knock-in mice recapitulate DYT1-related neuropathology.   
(A-C) Saggital sections of P10 brains immunostained with antibody against GFAP. (AI - 
CI) Higher magnification images of vulnerable regions (outlined in whole brain saggital 
section: cortex, ventral posterior thalamus, and deep cerebellar nuclei) stained for GFAP 
(brown, scale bars are 100 µm) and (AII - CII) Ubiquitin (red, scale bars are 10 µm). 
Similar appearing abnormalities were observed in Tor1ai-∆E/i-∆E and Tor1ai-∆E/- mice. 
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Figure II.5 Increased Tor1ai-∆E gene dosage rescues neurodegeneration.  
(A) Representative image of Nissl stained coronal brain section displaying deep 
cerebellar nuclei (DCN) counted. B. Examples of Nissl stained DCN neurons counted 
using unbiased stereology. Scale bars = 20 µm. C. Quantification of DCN neurons 
demonstrates that increasing Tor1ai-∆E  gene dosage rescues neurodegeneration. Means ± 
SEM for each genotype are displayed. (n = 5 per genotype) One-way ANOVA; F2,12 = 
4.425 P value = 0.0363 and Tukey’s multiple comparisons test, *.  
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Figure II.6 Hindbrain-selective induction of the DYT1 genotype (Tor1ai-∆E/+) does 
not cause abnormal twisting movements.  
(A) Sequencing of cDNA from mouse brain lysates of cortex or cerebellum. Wild type 
Tor1a sequence was detected in all samples except where En1 Cre recombinase acts to 
induce the ∆E mutation (e.g., cerebellum of En1 Cre+ Tor1aSwap/FLX mice). (B) 
Behavioral analysis of En1 Cre+ Tor1aSwap/+ mice. Control animals (Cre- Tor1a+/+ , Cre- 
Tor1aSwap/+, and En1 Cre+ Tor1a+/+) did not differ significantly from each other, so their 
data was combined for clarity. No significant differences were observed between control 
and En1 Cre+ Tor1aSwap/+ mice in any behavioral tests: tail suspension, horizontal grid 
hang tests; latency to cross balance beam; footslips per cross on balance beam. Means ± 
SEM for each genotype are displayed, with N within bar graph. 
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Figure II.7 Hindbrain-selective induction of the DYT1 genotype (Tor1ai-∆E/+) does 
not cause overt neuropathology.  
Cerebellar coronal sections from Tor1a+/+ and En1 Cre+ Tor1aSwap/+ mice: (A) Nissl, (B) 
GFAP and (C) ubiquitin immunostaining. The first column shows a low magnification 
view of cerebellum (scale bars = 500 µm) and subsequent columns show higher 
magnification detail of medial and lateral/interposed nuclei (scale bar = 100 µm).  
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Figure II.8 Crossing mice with Tor1aSwap and Tor1aFLX alleles allows for gene dosage 
analysis in vivo.  
Schematic representations of modified Tor1a genes demonstrates the differences between 
the Swap allele and the Floxed Tor1a allele (Liang et al., 2014). Half arrows indicate 
genotyping primer locations. Expected band sizes are shown. Inset displays genotyping 
results of  mice carrying various combinations of the wild type, Swap and FLX allele. We 
are able to distinguish between all genotypes through standard PCR techniques (See 
methods for additional information). 
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Figure II.9 Tor1ai-∆E/i-∆E and Tor1ai-∆E/- pups require extended weaning period.  
Pups were weaned when they reached a body weight of 7 grams or more. Means ± SEM 
for each genotype are displayed, with N in bar graph. One-way ANOVA; F5,74 = 36.83 P 
value < 0.0001, Tukey’s multiple comparison test, *. Experimental mice did not differ 
from each other, ns. 
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Figure II.10 Conditional knock-in mice recapitulate DYT1-related neuropathology 
in the Red nucleus.  
Red nucleus sections from Postnatal Day 10 mice stained for Nissl, GFAP, and ubiquitin 
(UBIQ). Scale bars are 10 µm. 
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Figure II.11 Conditional knock-in mice recapitulate DYT1-related neuropathology 
in the 7N Facial Nucleus.  
7N Facial Nucleus sections from Postnatal Day 10 mice stained for Nissl, GFAP, and 
ubiquitin (UBIQ). Scale bars are 10 µm. 
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CHAPTER III 
In vitro model of Tor1a loss-of-function recapitulates DYT1 Dystonia mouse 
phenotypes and reveals cell type specific vulnerability. 
Abstract 
Isolated primary dystonia describes a group of debilitating movement disorders 
traditionally thought to manifest in the absence of neurodegeneration. The most common 
of which is DYT1 dystonia, an early-onset form caused by a dominant mutation in the 
gene TOR1A. The 3 base pair deletion mutation results in a partial loss-of-function (LOF) 
of the encoded protein torsinA. Recently developed torsinA LOF mouse models reveal 
that distinct sensorimotor nuclei experience neural toxicity, evidence of altered protein 
quality control, and cell death. With this knowledge, I developed and characterized an in 
vitro cell culture model in order to facilitate a better understanding of the molecular 
consequences of torsinA dysfunction. Here, I present a primary cortical culture derived 
from LOF mice, that recapitulates in vivo phenotypes as well as cell-type specific 
susceptibility. Going forward, this system directs attention to a relevant neuronal 
population for addressing the impact of torsin LOF. Identification of the cortical subtype 
specifically vulnerable to torsinA LOF sheds light on mechanisms behind abnormal 
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motor output observed in disease-manifesting mouse models, thus introducing new 
hypotheses for circuit dysfunction in DYT1 dystonia patients.  
Introduction 
Dystonia describes a movement disorder that manifests as intermittent or sustained 
muscle contractions that cause involuntary movements and abnormal posture due to 
aberrant signaling from the CNS. When these movements are observed in the absence of 
overt neuropathology, they are referred to as primary dystonia. The most common form 
of primary dystonia, DYT1, is caused by a dominantly inherited 3 base pair in-frame 
deletion in the gene TOR1A, resulting in the loss of a single glutamic acid (∆E) from the 
encoded protein torsinA. TorsinA, a member of the AAA+ ATPase family, is a resident 
protein of the endoplasmic reticulum/nuclear envelope (ER/NE) luminal space. Although 
its exact functions are unclear, torsinA is a molecular chaperone that uses the hydrolysis 
of ATP to facilitate protein folding or disassembly of protein complexes. 
To date, knowledge of the molecular function of torsinA is derived from either 
immortalized and non-neuronal cell lines (Giles et al., 2009) (Nery et al., 2011; 
Goodchild & Dauer, 2005; Vulinovic et al., 2014; Jungwirth et al., 2011; Nery et al., 
2008; Valastyan & Lindquist, 2011) or mouse and human derived fibroblasts (Maric et 
al., 2014; Nery et al., 2011; Nery et al., 2008). Artificial cell lines require exogenous 
expression of torsinA, thus introducing the caveat of protein overexpression. Fibroblasts 
have the unique advantage of being acquired from DYT1 patients, however they lack 
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specific aspects unique to the neuronal environment that are of great importance to 
torsinA biology. In addition, torsinB, a homolog of torsinA, is known to play a larger role 
in non-neuronal cell types (Kim et al., 2010). Nevertheless, these studies suggest that 
torsinA plays an important role in protein quality control pathways in the ER (Nery et al., 
2011; Liang et al., 2014). At the NE, torsinA likely has a role involving the linker of 
nucleoskeleton and cytoskeleton (LINC) complex (Jungwirth et al., 2011; Nery et al., 
2008) and may influence nuclear pore complex organization (VanGompel et al., 2015) 
and megaRNP export processes (Jokhi et al., 2013). To confirm torsinA’s participation in 
these cellular mechanisms, the field requires a mammal-derived neuronal in vitro model 
in which torsinA levels can be manipulated endogenously within nuclei specifically 
susceptible to torsinA LOF. 
Disease-manifesting conditional knockout mice developed in our lab place us in the ideal 
position to develop an in vitro model to better understand the cellular consequences of 
torsinA dysfunction. Our knockout mice provide key insights on temporal and anatomical 
requirements of torsinA function. Studying these models, we found that torsinA likely 
plays a significant role during early maturation of the CNS with distinct motor nuclei 
vulnerable to the loss of normal torsinA function (thalamus, red nucleus, deep cerebellar 
nuclei, striatal cholinergic interneurons, and a layer-specific subset of the cortex) (Pappas 
et al., 2015; Liang et al., 2014). These regions exhibit reactive gliosis signifying neuronal 
toxicity, ubiquitin accumulation indicative of altered protein quality control, and cell 
death. These animals also display abnormal motor behaviors making them the first 
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manifesting models of DYT1 dystonia. These mice reveal a previously missed 
neuropathology and lead to the idea that DYT1 may arise from a motor circuitry with 
subtle, but acute neurodegeneration instead of a situation of normal structure-abnormal 
function. 
With this knowledge, I pursued an in vitro model of torsinA dysfunction in order to 
facilitate a better understanding of the cellular consequences leading to neural toxicity 
and ultimately neurodegeneration in disease-manifesting mouse models. Since torsinA 
function appears to be required during a specific window of circuit maturation and one of 
our identified vulnerable regions includes the cortex, I chose to pursue a primary cortical 
neuronal culture. This method allows for analysis at a higher resolution than is possible in 
tissue, at both a temporal and cellular level. I recapitulated neuropathology observed in 
conditional mouse models of DYT1 dystonia in an in vitro setting by culturing neurons 
from newborn Tor1ab and Tor1a null mice, demonstrating that neither the environment of 
the brain nor an intact circuit is required for torsin LOF abnormalities to occur. Among 
the phenotypes observed in vitro are perinuclear ubiquitin accumulation, abnormal 
nuclear pore complex organization, altered ER staining, and increased cell death. 
A major goal for this project was to identify the subpopulation of cortical neurons that 
appeared to be distinctly vulnerable to torsinA LOF in our conditional mouse models 
(Liang et al., 2014). We hypothesized that projection neurons of the infragranular layers 
are specifically susceptible to torsinA LOF. Culturing primary cortical neurons from 
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newborn Tor1a null pups enabled me to look for vulnerable cell populations and identify 
their layer identity. The perinuclear ubiquitin accumulation phenotype allowed me to 
identify this population as layer 5 pyramidal neurons that co-express markers CTIP2 and 
SATB2.  
Incorporating cortical cultures generated from newborn conditional knock-in Tor1ai-∆E 
mice  allowed for an assessment of gene dosage as I previously tested in vivo (See 
Chapter II). We predicted mutant torsinA can provide enough function to protect cortical 
neurons from developing perinuclear ubiquitin accumulation. My results were consistent 
with in vivo gene dosage experiments that demonstrate ∆E-torsinA retains partial function 
(Chapter II). I found considerably fewer neurons exhibiting perinuclear ubiquitin 
accumulation suggesting more torsinA available, regardless of the mutated state, is 
beneficial to this neuronal population.  
Characterization thus far of this unique cell model presents the idea that a specific 
population of layer 5 pyramidal neurons are susceptible to torsinA LOF. Going forward 
this work gives researchers the tools necessary to ask why this population is more 
vulnerable and in what cellular pathways torsinA likely plays a role. Development of this 
tool provides an easily manipulable system giving us and others the opportunity to ask 
questions about disease mechanism. 
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Results 
Torsin LOF abnormalities observed in mice are recapitulated in vitro 
To establish an in vitro model of torsin LOF, I first cultured primary cortical neurons 
from  postnatal day 0 (P0) pups that lacked both torsinA and torsinB in the CNS (Nestin 
Cre+ Tor1abFLX/KO). With the additional loss of this second torsin family member, we 
eliminate the regional vulnerability observed in torsinA LOF models (unpublished data, 
Dauer Lab). Tor1ab null neurons display perinuclear ubiquitin accumulation and 
disorganized nuclear pore complex staining in culture (Figure III.1). Perinuclear ubiquitin 
accumulation is an in vivo phenotype shared by conditional Tor1a knock-out and Tor1ai-
∆E knock-in mouse models in our lab (Chapter II and (Liang et al., 2014)). Ubiquitination 
signals for cellular machinery to degrade mis-folded proteins via the ubiquitin 
proteasome system (Ciechanover & Kwon, 2015). Ubiquitin aggregates therefore indicate 
an altered protein quality control system. The perinuclear pattern may be explained by 
mis-localization of endoplasmic reticulum associated degradation (ERAD) machinery 
within the ER-NE endomembrane system (Liang et al., 2014). The nuclear pore complex 
consists of ~30 nucleoporins (Nups) that create a diffusion barrier and facilitate nuclear 
import and export processes (Wente & Rout, 2010). Torsin ATPases have been linked to 
the mis-localization of specific nucleoporins (Nups) in C. elegans (VanGompel et al., 
2015). One of the implicated Nups, NPP-9, is conserved in mammals and is labeled by 
the antibody used to visualize nuclear pore complexes in this study (mab414, (Galy et al., 
2003; Aris & Blobel, 1989)). This data further implicates torsinA’s role in the proper 
localization of NPCs. Whether disorganized nuclear pore complex staining is a reflection 
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of the torsinA LOF-specific NE abnormality, NE budding, remains an unclear but 
intriguing area of interest (For example see Figure II.1 or (Goodchild et al., 2005)). The 
described abnormalities are observed as early as the fifth day in vitro (DIV5), but become 
more prominent and homogenous as the culture matures (Figure III.2).  
Tor1ab null neurons also appear to have altered ER staining when compared to control 
neurons (Figure III.3). KDEL staining identifies the C-terminal sequence that directs 
retrieval of ER resident proteins to the ER after post-transcription modifications have 
taken place in the Golgi apparatus (Capitani & Sallese, 2009). I observed a perinuclear 
distribution of KDEL staining in Tor1ab null neurons. If this perinuclear staining does not 
represent a complete rearrangement in ER structure morphology, it could signify a major 
failure in ER retrieval systems. To begin to address this question, I stained the cultures for 
the ER integral membrane protein calnexin and observed normal staining compared to 
control. ER disorganization may be explained by a decrease in the overall health of the 
neurons, as dendrites in Tor1ab null cultures begin to deteriorate at DIV15 followed by 
death of the culture by DIV21.  
TorsinA null cultures reveal cell type specific vulnerability 
Following my initial observations, I chose to move to a less severely affected model that 
better represents the human disease. I generated primary cortical cultures from P0 pups 
that lack torsinA within the CNS (Nestin Cre+ Tor1aFLX/FLX). With this application, I 
aimed to test the hypothesis that a specific cell type within the mouse cerebral cortex is 
!76
distinctly susceptible to the loss of torsinA function. To achieve this, I co-stained cultures 
with markers of specific cortical layers and the ubiquitin antibody. From histopathology 
observed in conditional knock-in and knockout mice, I hypothesized this population to be 
deep layer projection neurons (Liang et al., 2014). 
Tor1a null cultures recapitulate the cell type specificity observed in histological 
investigations of conditional knockout mice. Perinuclear ubiquitin accumulation was 
observed in a small fraction of the cultured neurons by DIV7 (0.077%, Figure III.2). This 
vulnerable population nearly triples in size by DIV15 (0.22%), but remains a small 
percentage of the total culture. These results explain why other attempts at culturing 
primary neurons from torsinA LOF or mutant mice yielded inconclusive results (Kim et 
al., 2010). By focusing future studies on this minority population, we should be able to 
elucidate previously missed molecular pathways affected by torsinA LOF.  
The mammalian cerebral cortex is composed of pyramidal excitatory projection neurons 
organized into diverse layers as well as GABAergic interneurons evenly distributed 
throughout all areas. Recent work has clarified the diversity of pyramidal neurons even 
within the same cortical lamina (Sorensen et al., 2015; Leyva-Diaz & Lopez-Bendito, 
2013; Fame et al., 2011). Neurons within each layer can be further distinguished based on 
hodology, morphology, and electrophysiological properties, however the antibodies 
available to study these unique populations remain rudimentary. I chose the molecular 
markers CTIP2 and SATB2 because they each highlight a distinct population within layer 
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5/6 pyramidal neurons and stained for nearly mutually exclusive populations in my 
cortical cultures. CTIP2, a zinc finger transcription factor, is reported to direct the 
projection of layer 5/6 pyramidal neurons to innervate subcortical targets (Chen et al., 
2008). SATB2 is an AT-rich sequence DNA binding transcription factor that is expressed 
in callosal projection neurons residing in layers 2-4 and a minority of callosal projection 
neurons within layer 5 (Szemes et al., 2006) (Alcamo et al., 2008; Britanova et al., 2008). 
SATB2 is believed to inhibit the expression of CTIP2, preventing subcortical targeting of 
SATB2+ pyramidal neurons (Gyorgy et al., 2008; Britanova et al., 2008) (Alcamo et al., 
2008). As a result, SATB2 expressing neurons cross the midline via the corpus callosum 
and innervate the contralateral cortex.  
Proper development of forebrain circuitry is directed by tight coordination of 
transcription factors, guidance molecules, and interactions among cortical neurons 
(Leyva-Diaz & Lopez-Bendito, 2013). Although conditional knock-in and knockout mice 
show grossly normal development of the cerebral cortex (Chapter II and (Pappas et al., 
2015; Liang et al., 2014)), it remains possible that some cortical cell types experience 
subtle impacts and thus could be disproportionally expressed in my cultures. Along these 
lines, patient fibroblasts were observed to have altered migration in vitro, suggesting 
altered brain development may be a consequence of torsinA LOF (McCarthy et al., 2012). 
Before asking which cell type within the Tor1a null culture displays perinuclear ubiquitin 
accumulation, I evaluated whether each cell type of interest is appropriately represented. 
Due to the cell death observed in the Tor1ab null cultures beginning at ~DIV18, I chose 
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to focus on a time point with presumably less cell death, but still at a peak in 
susceptibility. I found that DIV15 Tor1a null cultures display a comparable percentage of 
CTIP2+, SATB2+, and CTIP2/SATB2 co-expressing neurons  compared to control 
(Figure III.4). This suggests development of these cortical cell types are normal. To 
identify the fraction of cortical neurons vulnerable to torsinA LOF, I co-stained cultures 
with ubiquitin, CTIP2, SATB2, and DAPI. I found that the majority of neurons displaying 
torsinA LOF phenotypes were co-expressing CTIP2 and SATB2 (One-way ANOVA and 
Tukey’s multiple comparison tests P < 0.0001) (Figure III.5). Interestingly, this 
population makes up a small proportion of the cultured neurons (< 20%) (Figure III.4C).  
Retained function of ∆E-torsinA in vitro suppresses perinuclear ubiquitin 
accumulation 
I examined the impact of the ∆E mutation on the aforementioned in vitro phenotypes by 
culturing dissociated cortices dissected from P0 pups homozygous for CNS expression of 
the conditional Tor1ai-∆E allele (Nestin Cre+ Tor1aSwap/Swap = Tor1ai-∆E/i-∆E in the CNS). 
Homozygous neurons displayed some fluctuations in proportions of the cell types of 
interest when compared to control and Tor1a null cultures (Figure III.6). There was a 
decrease in the number of CTIP2 positive cells present compared to Tor1a null cultures 
(One-way ANOVA; P = 0.0353), however this difference was not observed when 
compared to control using Tukey’s multiple comparison post-hoc analysis. I also found 
that there were fewer SATB2 cells expressing CTIP2 immunofluoresence (One-way 
ANOVA; P = 0.0088) suggesting that at least some of the lost CTIP2 positive cells are 
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from the vulnerable CTIP2/SATB2 population. Importantly, I did not see a significant 
decrease in the preposed vulnerable population in Tor1ai-∆E/i-∆E cultures (One-way 
ANOVA; P = 0.2933) (Figure III.6C). In accordance with in vivo data (Chapter II), I 
found that homozygous expression of ∆E-Tor1a protects the cortical neurons from 
perinuclear ubiquitin accumulation (Paired t-test; P = 0.0224) (Figure III.7). Although a 
substantially lower number of neurons display torsinA LOF abnormalities in the Tor1ai-
∆E/i-∆E culture, the same CTIP2/SATB2 population appears to be vulnerable (One-way 
ANOVA and Tukey’s multiple comparison; P = 0.0049) (Figure III.8). Identifying the 
same vulnerable population in two different genetic manipulations of the Tor1a gene 
strengthens strengthens the finding that this population is one uniquely affected by 
torsinA LOF.  
Discussion 
The aim of this project was to establish an in vitro system that accurately represented 
events occurring in our conditional mouse models of DYT1 dystonia. I observed several 
phenotypes that mimic our in vivo findings by culturing dissociated cortical neurons from 
our mouse lines. This leads to the conclusion that neither the circuit nor the environment 
of the brain is required for torsin LOF abnormalities to occur. My in vitro model allowed 
me to identify the cortical cell type distinctly susceptible to loss of normal torsinA 
function as a minority population of neurons  within layer 5 that co-express transcription 
factors CTIP2 and SATB2 (see Figure III.9 for proposed model). I also confirmed 
previous work that showed ∆E-torsinA retains partial function, emphasizing the idea that 
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having more torsinA available is important regardless of the mutated state (Chapter II and 
(Liang et al., 2014)). This tool shows promise for pushing the field of DYT1 dystonia 
forward by facilitating investigations of the molecular consequences of torsin LOF and 
the impact that torsinA LOF has on a major sensorimotor nuclei.  
By culturing dissociated cortical neurons from conditional Tor1a mutant mice, I was able 
to recapitulate in vivo observations in an in vitro setting. The phenotypes I observed 
followed a developmental onset and correlated with the dosage of torsin proteins present. 
These phenotypes included possible structural changes to the ER-NE endomembrane 
system, perinuclear ubiquitin accumulation, and increased cell death. I also found 
evidence of altered staining of ER resident proteins which calls for further investigation 
of KDEL-driven retrieval mechanisms. All cortical neurons appeared to be susceptible to 
these torsin LOF phenotypes when both torsinA and torsinB family members were 
deleted, whereas only a distinct subset of neurons were observed to be vulnerable when 
torsinB function was present. This restricted susceptibility mimics what we have 
observed in the mouse brain (unpublished data, Dauer Lab). Furthermore, the presence of 
two knock-in alleles appears to lessen the severity of these phenotypes. Taken together, 
the defined torsin LOF phenotypes are substantiated by the fact that they are observed in 
three independent manipulations of the torsin locus as well as in the mouse. This leads to 
the conclusion that these mechanisms are likely to be involved in disease pathogenesis. 
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Tor1ab null cultures exhibit nuclear pore complex disorganization, further emphasizing 
an important NE role for torsinA. Many studies define a role for torsin ATPases at the NE 
including the association with the LINC complex (Jungwirth et al., 2011; Nery et al., 
2008), nucleoporin localization (VanGompel et al., 2015), and megaRNP export (NE 
budding) (Jokhi et al., 2013). Altered nuclear pore complex distribution may impact gene 
transcription as the pore is an important docking site for transcriptional machinery 
(Wente & Rout, 2010). Protein synthesis may also be affected due to potential changes to 
two mechanisms of nucleocytoplasmic transport of mRNA (megaRNPs and nuclear 
pore). Development of the double knockout mouse that lacks both torsinA and torsinB 
(unpublished data, Dauer Lab) allowed for the generation of a homogenous culture of 
vulnerable neurons. This culture provides the much needed mammalian system for 
exploring torsin ATPase involvement in NE mechanisms.  
Due to increased gliosis, ubiquitin aggregation, and cleaved-caspase 3 staining 
concentrating within layers 5 and 6 in conditional Tor1a knock-out mouse brain sections, 
we suspected a cell type specific vulnerability within the cortex (Liang et al., 2014). 
These layers mostly consist of projection neurons that facilitate corticofugal and 
corticothalamic connections respectively. My cell culture model allowed me to identify 
this vulnerable cell type as pyramidal neurons (potentially originating from layer 5) co-
expressing molecular markers CTIP2 and SATB2. SATB2 normally labels callosal 
projection neurons and acts to downregulate the expression of CTIP2 (Leone et al., 
2014). Whether we are observing an inability to establish cellular fate or we are simply 
!82
catching these neurons during a critical switching point is unclear. This work illuminates 
the possibility that these neurons are more susceptible to torsinA LOF because they are 
undergoing or attempting to undergo an important developmental switch. Nevertheless, 
identifying this population of neurons sheds light on what type of circuit changes could 
be blamed for the resulting abnormal motor behavior and directs future molecular studies 
to a relevant cell type surely to result in a clearer understanding of torsinA biology.  
Even though I confirmed normal representation of each cortical subtype of interest, this 
does not eliminate the possibility that migration is altered in our conditional mouse 
models. This study required me to rely on molecular markers traditionally used to 
distinguish between cortical layer populations (Leyva-Diaz & Lopez-Bendito, 2013) 
however a dissociated cortical culture eliminates any information on the physical origin 
of each neuron. Staining for these layer markers in mouse brain sections should verify 
appropriate migration. In Chapter IV of this dissertation, I propose in vivo experiments 
that address how these results can be confirmed in our mouse model and how we can 
build on these findings by determining the brain regions targeted by the identified 
vulnerable population. 
Other studies using cell lines that are not relevant to DYT1 dystonia have provided the 
field with insights into normal torsinA biology, however thus far torsinA’s physiological 
substrates remain unknown. The cell model presented here can hopefully provide new 
ways to explore the role of torsinA in the cell. Previous assessments of primary cortical 
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neuron cultures resulted in inconclusive findings (unpublished data, Dauer Lab). The 
small percentage of neurons displaying the perinuclear ubiquitin phenotype explain why 
this minority population was missed in the past. Identification and isolation of the 
susceptible cortical subtype should prevent dilution of future molecular or biochemical 
assessments. Confirmation of previously reported roles in this relevant cell type will 
strengthen each independent study. 
This project provides an accessible model to study DYT1 dystonia pathogenesis by 
providing a cell culture system that recapitulates specific phenotypes observed in disease 
manifesting mice and reveals a cortical subtype distinctly susceptible to loss of normal 
torsinA function. This is a necessary tool currently lacking in the field, and shows 
promise for leading to a better understanding of torsinA function and the circuit 
abnormalities at work in conditional knockout mouse models. 
Materials and Methods 
Mice 
This chapter investigated 3 experimental genotypes along with littermate controls. All 
cortical cultures in this study were generated by dissociating cortices of postnatal day 0 
pups. For each experiment, one experimental pup and one Cre negative control were 
cultured. Nestin Cre recombinase mediated Tor1ab knockout mice (Nestin Cre+ 
Tor1abFLX/KO) were generated by crossing Nestin Cre+ Tor1ab+/KO mice with Cre 
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negative Tor1abFLX/FLX mice (unpublished data, Dauer Lab). Due to early perinatal 
lethality of Nestin Cre+ Tor1abFLX/KO pups, cortical dissections were performed on the 
entire litter on postnatal day 0. Cortices were stored in ice cold Hibernate E (BrainBits®; 
HE) while PCR genotyping was completed. Nestin Cre recombinase mediated Tor1a 
knockout mice (Nestin Cre+ Tor1aFLX/FLX) were generated by crossing Nestin Cre 
Tor1aFLX/+ mice with Cre negative Tor1aFLX/FLX mice (Liang et al., 2014). Homozygous 
mice for the conditional knock-in allele (Nestin Cre+ Tor1aSwap/Swap) were generated by 
crossing Nestin Cre+ Tor1aSwap/+ mice with Cre negative Tor1aSwap/Swap mice (Chapter II).  
Coating of coverslips for primary cortical culture 
Coverslips (Fisher Scientific; 12-545-80 12CIR.-1) were sterilized for cell culture by 
washing with 5% Triton X100 (Fisher Scientific; BP151) for 30 minutes on a shaker 
followed by rinsing with sterile water. Coverslips were washed with a solution that was 
5% Glacial Acetic Acid (Fisher Scientific; A28-212) and 75% Ethanol. Next, coverslips 
were washed in increasing concentrations of Ethanol and stored in 100% Ethanol at 4 
degrees C until use.  
Prior to culture, coverslips were washed with sterile H2O, transferred to 24 well plates (1 
slip/well), and coated with PDL (Poly-D-Lysine, Sigma; P0899) diluted in Borate Buffer 
(Sodium Tetraborate decahydrate, Sigma; B9876 and Boric Acid, Sigma; B7901). 
Coating was performed by placing 50 µL of 0.1 mg/mL PDL on each coverslip, covering 
the plate with Parafilm® (Sigma; P7793) and placing at room temperature overnight for 
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incubation. Coverslips were protected from light during this time. Following coating, 
coverslips were thoroughly washed with sterile H2O and allowed to dry for 15 minutes. 
Coated coverslips were used immediately or stored at 4 degrees C until needed.  
Primary cortical culture 
Methods used to culture cortical neurons from P0 pups were adapted from Beaudoin and 
colleagues (Beaudoin et al., 2012). P0 pups identified for culturing were sacrificed by 
decapitation. Immediate dissection of the brain and cortices took place in ice cold 
Neurobasal A media (GIBCO; 15090-046). Dissected cortices were stored in Hibernate E 
(BrainBits®; HE) until all pups were dissected or until genotyping was performed.  
Centrifugation of cortices was performed at 50 RCF for 3 minutes in order to remove 
Hibernate E solution. Cortices were trypsinized in 2.5% Trypsin (GIBCO; 15090-046) + 
0.1% DNAse I from Bovine Pancreas (Sigma; D4263) diluted in Hanks’ Balanced Salt 
Solution (GIBCO; 14175-095) for 15 minutes in a 37 degree C water bath. Cortices were 
agitated gently and then centrifuged at 1000 RCF for 3 minutes to remove trypsin 
solution. Cortices were washed with Hanks’ Balanced Salt Solution twice including 
gentle agitation and centrifugation (3 minutes at 1000 RCF) each time. After washing, 
500 µL of culturing media (Neurobasal A treated with B27 Supplement (GIBCO; 
17504-044), Penicillin Streptomycin (GIBCO; 15070) and Glutamax (GIBCO; 
35050-061)) was added to cortices. Dissociation was performed first with 1000 µL wide 
bore pipette tips followed by standard 1000 µL pipette tips. After single cell suspension 
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was reached, the 500 µL suspension was transferred to a new 50 mL tube via a 40 µm 
nylon cell strainer (BD Falcon; 352340). A cellular concentration was found from the 
resulting suspension using a hemacytometer. Neurons were plated at a concentration of 
600,000 cells/mL by performing necessary dilutions in the culturing media. For plating, 
80 µL of diluted neurons were added to each coverslip resulting in ~48,000 neurons per 
coverslip. Plates were then placed in a 37 degree C incubator with 5% CO2 for 1.5 hours. 
After initial incubation, 500 µL of warmed culturing media was added to each well. 
Neurons were kept in this incubator until experimental endpoints. No feeding was 
required and neurons were able to survive using this technique up to approximately 6 
weeks (except for Tor1ab null neurons, these cultures died by 3 weeks).  
Immunocytochemistry 
Cultured neurons were fixed using 4% paraformaldehyde (Electron Microscopy Services; 
15710) 4% sucrose (Sigma; S0389) in 1X Phosphate Buffered Saline, PBS, (Sigma; 
P3813) warmed to 37 degrees C for 10 minutes. Following fixation, neurons were 
permeabilized for 10 minutes using 0.3% Triton X100 (Fisher Scientific; BP151) in 1X 
PBS. Cells were washed 3 times with the permeabilization solution prior to blocking with 
10% Normal Donkey Serum (Jackson ImmunoResearch; 017-000-121) in 1X PBS for 1 
hour at room temperature. Primary antibody incubation was performed overnight at 4 
degrees C with shaking. Primary antibodies were diluted in 1% Normal Donkey Serum 
and 0.3% Triton X100 1X PBS as follows: nuclear pore complex (Abcam; ab24609 
1:300), ubiquitin (Dako Z0458; 1:2000), KDEL (Enzo Life Sciences; 10C3 1:500), 
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calnexin (Enzo Life Sciences; SPA-860 1:200), CTIP2 (Abcam; ab18465 1:300), SATB2 
(Abcam; ab51502 1:300). Three washes with 1X PBS followed primary antibody 
incubation. Secondary antibody incubation was for one hour at room temperature with 
shaking. Secondary antibodies were diluted 1:500 in 1X PBS. Fluorescent antibodies 
included: Alexa Fluor® 555 Donkey Anti-Rabbit IgG, Life Technologies A31572, Alexa 
Fluor® 488 Donkey Anti-Rabbit IgG, Life Technologies A21206, Alexa Fluor® 647 
Donkey Anti-Rabbit IgG, Life Technologies A31573, Alexa Fluor® 555 Donkey Anti-
Mouse IgG, Life Technologies A31570, Alexa Fluor® 488 Donkey Anti-Mouse IgG, Life 
Technologies A21202, Alexa Fluor® 488 Donkey Anti-Rat IgG, Life Technologies 
A21208. A final three washes with 1X PBS followed secondary antibody incubations. 
Prolong Gold + DAPI (Life Technologies; P36931) was used to mount coverslips on 
microscope slides (Fisherbrand® Superfrost Plus Fisher Scientific; 12-550-15). Slides 
were kept at room temperature for 24 hours then moved to storage at 4 degrees C. 
Analysis of staining took place at least 48 hours after staining to ensure mounting 
medium had appropriately cured allowing for maximum fluorescence. Imaging was 
completed using a Axioskop2 microscope (Carl Zeiss Microscopy, USA) and an Olympus 
digital camera (model DP70, USA) (Figure III.2 and Figure III.5B). Confocal imaging 
was performed at University of Michigan’s Microscopy and Image Analysis Laboratory 
using a Leica Inverted SP5X 2-photon confocal microscope (Figure III.3) and a Leica 
TCS SP8 2-photon confocal microscope with a LIAchroic beam splitter (Leica 
Microsystems GmbH, Germany) (Figure III.1). 
!88
Analysis of torsin LOF cultures 
To evaluate the general composition of each neuronal culture I first evaluated the percent 
of cells expressing each cortical subtype marker. Random fields of view were chosen 
using the DAPI channel. The number of DAPI cells in each view was recorded. Using the 
DAPI staining, it was possible to distinguish between neurons (discernible 
heterochromatin) and glia (small, bright fluorescence). Glia were not included in the 
DAPI counts. For each field of view, the fluorescence channel was switched to count the 
number of neurons expressing other subtype-specific markers (i.e. CTIP2, SATB2). The 
channel was then switched back to DAPI to find another field of view. This was repeated 
until 200 DAPI neurons were counted per coverslip. Percentage of cortical subtypes per 
culture were calculated by dividing the number of neurons expressing a particular 
subtype marker by 200. This number was multiplied by 100 to convert to a percentage. 
For each experiment, two coverslips were counted per pup cultured and averaged to 
produce one data point. 
To quantify the number of cells with perinuclear ubiquitin aggregates per coverslip, each 
coverslip was scanned using a 40x objective. Two coverslips were counted per pup 
cultured and averaged to produce one data point. 
To determine the identity of the cells with perinuclear ubiquitin aggregates, each 
coverslip was scanned using a 40x objective on the channel expressing the fluorescently 
tagged ubiquitin antibody. Each time a cell was found with perinuclear ubiquitin 
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aggregates, the other channels were examined to determine whether that cell was positive 
for CTIP2 and/or SATB2. This was repeated for the entire coverslip or until 100 cells 
with aggregates were identified. Two coverslips were counted per pup cultured and 
averaged to produce one data point.  
Statistical analysis 
GraphPad Prism statistical software (GraphPad Software, Inc., La Jolla, CA, USA) was 
used to analyze all data. Means are displayed with error bars representing SEM. Analysis 
included paired t-tests and One-way ANOVA tests. One-way ANOVAs were followed by 
post-hoc Tukey’s multiple comparison tests. Significance was determined to be a P value 
< 0.05. 
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Figure III.1 Torsin loss-of-function pathology is recapitulated in primary cortical 
cultures derived from Tor1ab null mice  
Immunostaining of primary cortical neurons from Tor1ab wild type (WT) and Tor1ab 
null mice for nuclear pore complex (A) and ubiquitin (B). Merged image includes DAPI 
staining (C). Dissociated cortical cultures fixed at DIV7.   
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Figure III.2 Minority population is vulnerable to Tor1a loss-of-function pathology  
Tor1ab wild type (WT) (A), Tor1ab null (B), and Tor1a null (C) primary cortical cultures 
stained for ubiquitin at DIV2, DIV7, and DIV15. Percentages listed for Tor1ab null 
cultures (B) are estimated because number of neurons with perinuclear ubiquitin 
accumulation were too numerous to count. Percentages listed for Tor1a null cultures (C) 
were calculated by counting the number of neurons per coverslip with perinuclear 
ubiquitin accumulation and dividing by number of plated neurons (48,000 cells/slip).  N 
= 2 biological replicates for DIV7, N = 5 biological replicates for DIV15. Arrows 
indicate neurons displaying prominent perinuclear ubiquitin aggregation. 
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Figure III.3 Tor1ab null neurons feature altered staining of ER-retention signal 
KDEL with normal ER morphology  
Immunostaining of primary cortical neurons from Tor1ab wildtype (WT) and Tor1ab null 
mice for ER retention signal, KDEL (A) and ER integral membrane protein calnexin (B). 
Merged image for calnexin includes DAPI staining (blue). Dissociated cortical cultures 
fixed at DIV7. 
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Figure III.4 Composition of Tor1a null primary cortical culture is not different from 
control  
(A) Paired t-test; P = 0.1612, ns (B) Paired t-test; P = 0.2437, ns (C) Paired t-test; P = 
0.2249, ns (D) Paired t-test; P = 0.9229, ns (E) Paired t-test; P = 0.2032, ns. CTL = Cre 
recombinase negative control. All counts performed at DIV15. Each data point represents 
an average of two coverslips generated from one pup. Error bars represent SEM. 
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Figure III.5 Neurons co-expressing CTIP2 and SATB2 are selectively vulnerable to 
torsinA loss-of-function-mediated perinuclear ubiquitin accumulation  
(A) Identity of vulnerable neurons observed at DIV15. One-way ANOVA and Tukey’s 
multiple comparison test; P < 0.0001, *. Two coverslips counted and averaged per pup (N 
= 3 pups). Mean percentage is displayed and error bars represent SEM. (B) Example of 
vulnerable neuron co-expressing CTIP2 and SATB2. 
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Figure III.6 Composition of Tor1ai-∆E/i-∆E primary cortical culture does not explain 
decrease in number of cells with perinuclear ubiquitin accumulation  
All counts performed at DIV15. Each data point represents an average of two coverslips 
generated from one mouse pup. Error bars represent SEM. (A) One-way ANOVA and 
Tukey’s multiple comparison test; P = 0.0353, ns (B) One-way ANOVA and Tukey’s 
multiple comparison test; P = 0.0558, ns (C) One-way ANOVA and Tukey’s multiple 
comparison test; P = 0.2933, ns (D) One-way ANOVA and Tukey’s multiple comparison 
test; P = 0.9282, ns (E) One-way ANOVA and Tukey’s multiple comparison test; P = 
0.0088, ns. 
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Figure III.7 Increased gene dosage of Tor1ai-∆E protects neurons from perinuclear 
ubiquitin accumulation 
All counts performed at DIV15. Each data point represents average of two coverslips 
generated from one mouse pup. Error bars represent SEM. Paired t-test (one tailed) P = 
0.0224, *. 
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Figure III.8 Neurons co-expressing CTIP2 and SATB2 are selectively vulnerable to 
torsinA loss-of-function-mediated perinuclear ubiquitin accumulation  
Identity of vulnerable neurons observed at DIV15. Two coverslips counted and averaged 
per pup (N = 4 pups). Mean percentage is displayed and error bars represent SEM. One-
way ANOVA and Tukey’s multiple comparsion test; P = 0.0049, *.  
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Figure III.9 Model of cortical population specifically vulnerable to torsinA loss-of-
function 
Image modified from (Fame et al., 2011) to show majority of vulnerable population co-
expresses SATB2 and CTIP2 and likely originates from layer V. Layers are numbered in 
roman numerals. WM, white matter.  
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CHAPTER IV 
Future Directions 
The main components of my dissertation work were the development and 
characterization of two novel approaches for studying DYT1 dystonia pathogenesis. 
Throughout this chapter I will emphasize the power of using these tools to build a better 
understanding of torsin biology and primary dystonia. I will expand on previously 
discussed conclusions and introduce new hypotheses that should be tested to hopefully 
move the field forward and provide strategies for better targeted therapies for DYT1 
dystonia patients.  
Conditional knock-in mouse model of DYT1 Dystonia 
The genetic tools described in this dissertation are important for studying the effects of 
the DYT1 mutation in vivo. Previous mouse models that allow for endogenous expression 
of the DYT1 mutation resulted in either perinatal lethality (Goodchild et al., 2005) or 
produced mice without overt motor behaviors (Tanabe et al., 2012; Dang et al., 2005). 
Others rely on exogenous expression of a mutated human transgene and thus have the 
caveat of protein overexpression (Shashidharan et al., 2005; Sharma et al., 2005; Page et 
al., 2010; Grundmann et al., 2012). To combat these issues, we genetically engineered a 
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Tor1a allele that remains wild type until Cre recombinase is active. This allows 
researchers to conditionally express endogenous levels of ∆E-torsinA within discrete cell 
types and at specific times during development. This genetic tool eliminates lethality 
observed in germline homozygous mice and expands observations to disease relevant 
behaviors. I used this model to study loss-of-function (LOF) and gain-of-function (GOF) 
properties of ∆E-torsinA. This work provides further evidence that the DYT1 mutation is 
a partial LOF mutation as I did not find any evidence to support GOF toxicity. In a 
separate section below, I discuss how this result will influence the field. This mouse 
model should aid future in vivo endeavors that aim to identify disease-causing circuit 
alterations. I demonstrated one example of this research strategy by expressing the DYT1 
genotype specifically in hindbrain nuclei. While I did not generate an abnormal behaving 
mouse, I was able to investigate an important hypothesis in the field. I will address the 
basis for this experiment and other methods we can pursue to further explore the merit of 
this hypothesis in a separate section below. 
In vitro model of torsinA LOF  
The conditional mouse models developed in our lab opened our eyes to the possibility 
that within a primary cortical culture, only a small subset of neurons are affected by 
torsinA LOF. This is exactly what I observed when culturing dissociated cortical neurons 
from Tor1a null mice. By recapitulating Tor1a LOF phenotypes in vitro, I solidified this 
strategy as a new approach for studying the molecular consequences of torsin LOF. 
Going forward, we can be more certain of any results found using this tool due to our 
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investigations taking place in a disease-relevant cell type. In addition, torsinA function is 
manipulated through the endogenous locus and at a time in development when torsinA 
function is vital. This work emphasizes the importance of evaluating previously 
published cell culture models with these same criteria—what cell type was used, what 
was the timing of the investigations, and how was torsinA function manipulated? 
Answers to these questions are needed in order to appreciate how relevant the findings 
are to disease pathogenesis. 
Past mouse work demonstrates that LAP1 knockout mice phenocopy torsinA knockout 
mice in both NE budding and perinatal lethality (Kim et al., 2010). This work emphasizes 
that torsinA and LAP1 function in the same molecular pathway. These findings and the 
fact that LAP1 is a potent activator of torsinA ATPase activity (Sosa et al., 2014; Brown 
et al., 2014),  led our lab to develop a mouse line that allows for conditional deletion of 
LAP1. Restricting deletion of Tor1a to the CNS circumvented perinatal lethality and 
resulted in a disease-manifesting mouse model (Liang et al., 2014), doing the same for 
LAP1, however, resulted in a mouse with severe hydrocephaly (unpublished data, Dauer 
Lab). This neuropathology is a major caveat that prevents us from fully investigating the 
distinct sensorimotor nuclei vulnerable in CNS-specific torsinA knockout mice. By 
culturing cortical neurons from LAP1 knockout pups I can look for recapitulation of 
torsinA LOF phenotypes (e.g.  perinuclear ubiquitin accumulation). This will help us 
identify what pathways and interactors are involved in the neuropathology we observe in 
our DYT1 dystonia mouse models.  
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DYT1 dystonia mutation is a partial loss of function mutation 
Both Tor1a knockout mice and mice homozygous for the ∆E mutation exhibit perinatal 
lethality and nuclear envelope structure abnormalities suggesting that the ∆E mutation is 
a LOF mutation (Goodchild et al., 2005). However, dominant inheritance and the single 
pathological mutation for TOR1A are both features of GOF mutations. The conditional 
knock-in ∆E-Tor1a mouse model allowed me to address the LOF and GOF properties of 
∆E-torsinA in vivo. I used this tool to evaluate the viability, neuropathology, and motor 
phenotypes of CNS-specific Tor1ai-∆E/i-∆E and Tor1ai-∆E/- littermates. Mice with two ∆E-
Tor1a alleles in the CNS did not result in a worse prognosis compared to mice with only 
one ∆E-Tor1a allele. In some instances Tor1ai-∆E/i-∆E mice demonstrated an improved 
phenotype (postnatal growth and deep cerebellar nuclei neurodegeneration). This in vivo 
gene dosage study allowed us to conclude there is no evidence for toxic GOF properties 
for the ∆E mutation. 
AAA+ proteins typically function as hexamers and use the hydrolysis of ATP to catalyze 
conformational changes of their substrates (Iyer et al., 2004). Recent in vitro studies 
indicate that LAP1 (or LULL1) hetero-oligomerizes with torsinA in order to produce a 
working AAA+ ATPase (Sosa et al., 2014; Brown et al., 2014). Biochemical work argues 
against the ability of ∆E-torsinA to hetero-oligomerize efficiently. The ∆E mutation is 
located at the interface that allows for torsinA’s association with LAP1/LULL1, 
contributing to the observed decrease in affinity and resulting ATPase activity (Kock et 
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al., 2006; Brown et al., 2014; Sosa et al., 2014; Zhu et al., 2010). Therefore, it is likely 
that to increase the efficiency of the complex, it is important to improve affinity of the 
mutated interface. Our data is consistent with the notion that ∆E-torsinA is a 
hypomorphic protein and thus predicts that therapeutics increasing the activity of the 
AAA+ ATPase enzymatic complex would be beneficial and would not enhance a GOF 
toxic effect. 
TorsinA-interacting proteins LAP1 and LULL1 only weakly activate ∆E-torsinA in vitro, 
and yet our in vivo findings verify ∆E-torsinA retains some activity (Chapter II and 
(Liang et al., 2014)). This suggests there may be other activators or unique factors within 
the in vivo environment that remain to be discovered. A genetic screen aimed at 
identifying additional putative activators and the still unknown torsinA substrates is 
important for moving the field of torsinA biology and DYT1 dystonia forward. Another 
explanation for ∆E-torsinA’s retained function in vivo is one of structural nature rather 
than ATPase activity. Neurodevelopmental events such as neurogenesis, neural tube 
closure, and migration, all depend on tight coordination among cytoskeletal, NE proteins, 
and the nucleoskeleton (Gerace & Huber, 2012; Worman & Gundersen, 2006). TorsinA is 
known to associate with linker of the nucleoskeleton and cytoskeleton (LINC) complex 
proteins (Nery et al., 2008; Jungwirth et al., 2011; Atai et al., 2012) and ∆E-torsinA has a 
GOF association with the LINC complex protein, SUN1 (Jungwirth et al., 2011). 
Furthermore, the aforementioned activating protein LAP1, is in direct association with 
nuclear lamina (Foisner & Gerace, 1993). These associations posit the idea that torsinA 
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may play a role in the maintenance of this structural network in conjunction with or 
outside of its ATPase activity.  
The two experimental genotypes in our gene dosage study reported in Chapter II (CNS-
specific Tor1ai-∆E/i-∆E and Tor1ai-∆E/-) do not directly address the possibility that ∆E-
torsinA may only be toxic in the context of the wild type protein, however one of the 
included littermate controls is the heterozygote Tor1ai-∆E/+. This genotype expressed in 
mice has been extensively studied (Tanabe et al., 2012; Dang et al., 2005). The lack of an 
overt motor behavior in these mice demonstrates that if there is a dominant negative 
effect of the ∆E protein on the wild type protein, it is not severe enough to disrupt cellular 
function thereby leading to abnormal motor circuitry. Consistent with this idea is the fact 
that overexpressing mutant forms of torsinA in mice does not lead to overt motor 
behaviors (Shashidharan et al., 2005; Sharma et al., 2005; Page et al., 2010; Grundmann 
et al., 2012). If it were a dominant negative phenomenon than overexpressing mutant 
protein should sequester an abundant amount, if not all of the wild type torsinA present 
leading to a phenotype that resembles complete Tor1a LOF (perinatal lethality).  
Defining the developmental window for torsinA function  
DYT1 is an early-onset form of dystonia with symptoms often developing during early 
adolescence. Several studies from our lab demonstrate torsinA is particularly important 
during a critical neurodevelopmental window that encompasses circuit maturation. 
Appearance of Tor1a LOF-mediated NE budding follows a caudal to rostral timeline, 
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correlating with the maturation of each brain region (manuscript in preparation). NE buds 
are first observed post-migration and are not found in adult mice. Resolution of NE buds 
follows the same caudal to rostral pattern. This leads to the idea that the NE budding 
phenotype is highlighting a vulnerable developmental period: post-migration to circuit 
maturation. Secondly, a DYT1 mouse line with neurodegeneration of cholinergic 
interneurons exhibits juvenile onset of dystonic behavior that coincides with a time in 
which striatal projection neurons and interneurons are becoming physiologically active 
(Pappas et al., 2015). Finally, the sensorimotor nuclei-specific neuropathology (gliosis 
and perinuclear ubiquitin accumulation) observed in conditional Tor1a LOF mouse 
models is absent at postnatal day 0, but occurs during the second week of life, a time in 
which the affected nuclei are integrating into a circuit (Chapter II and (Liang et al., 
2014)). These studies demonstrate an important disease mechanism for DYT1 Dystonia is 
loss of normal torsinA function during cellular processes specific to circuit maturation.  
A major goal for our lab is to identify a critical developmental window for torsinA 
function in vivo. We hypothesize that torsinA is not needed in the adult CNS. Clinical 
features that support this hypothesis include the fact that DYT1 patients reach a plateau 
with their disease symptoms and that carriers are unlikely to develop the disease if they 
reach ~27 years of age without manifesting symptoms. To test our hypothesis in the lab, 
we have employed Tor1aFLX/- mice in combination with either tamoxifen-inducible Cre 
recombinase mice or viral delivery of Cre recombinase. We have not witnessed any 
evidence of overt motor behavior or neuropathology when carrying out these 
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experiments. These findings support the hypothesis that torsinA is dispensable in the 
adult CNS. Unfortunately, due to technical difficulties related to the torsinA antibody, we 
are not satisfied with our Tor1a deletion efficiency. The new conditional knock-in mouse 
model of ∆E-Tor1a may allow us to overcome these technical limitations. By 
conditionally inducing the Tor1ai-∆E/- genotype in the brains of adult mice (using either 
tamoxifen Cre or viral delivery of Cre) we should be able to test whether the adult CNS is 
vulnerable to Tor1a LOF. In this experiment, validation of Cre recombination would 
require sequencing of cDNA instead of immunohistochemistry or western blot. If 
sequencing results in single peaks clearly indicating deletion of base pairs ‘GAG’ (single 
glutamic acid deletion, ∆E) we can trust our recombination strategy. Any evidence of 
double peaks like those seen in the heterozygous animal (Figure II.1C) would mean we 
cannot trust our behavior analysis. 
Conditional mouse models developed in our lab reveal the cortex as a region of 
susceptibility for Tor1a LOF (Chapter II and (Liang et al., 2014)). Cortical neurons in 
culture undergo several stages that mimic in vivo neurodevelopmental processes; neurite 
extension, synaptogenesis, and pruning (Polleux & Snider, 2010). Development of my 
Tor1a LOF cortical culture model provides the temporal resolution to address 
investigations at a time in which torsinA function is critical. We can now focus in on 
relevant developmental processes occurring during this critical window and elucidate the 
role of torsinA within the associated cellular mechanisms.   
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One unanswered question in our lab is regarding perinuclear ubiquitin accumulation (and 
NE budding described above) and whether neurons are able to resolve this phenotype or 
if the disappearance of this phenotype in adult animals is due to neurodegeneration of 
affected populations. In some of our conditional mouse models, regions identified to have 
neurodegeneration are distinct from those showing the perinuclear ubiquitin phenotype 
(unpublished data, Dauer Lab). This introduces a disconnect between ubiquitin 
aggregation and cell death. Establishing a timeline of the ubiquitin accumulation 
phenotype in my Tor1a LOF cell culture will begin to address this question. So far, I have 
only fully characterized the impact of torsinA LOF at 15 days in vitro (Chapter III). To 
address this question, analysis of mature (DIV21) Tor1a null cultures should be 
completed. A decrease in the number of neurons with ubiquitin accumulation would 
recapitulate what we see in our mice and signify either affected neurons have died or are 
able to resolve the ubiquitin phenotype. Measuring cell death in Tor1a null cultures can 
be used to address this result. Evidence for neurodegeneration in Tor1a null cultures 
would be consistent with observations in Tor1ab null cultures, where the entire culture 
exhibits the ubiquitin phenotype and ultimately dies before reaching DIV21. If cell death 
is comparable to control cultures, I would conclude that vulnerable neurons are able to 
resolve the ubiquitin aggregation phenotype. Alternatively, an increase in the number of 
vulnerable neurons at DIV21 may be observed. The increase of neurons showing 
perinuclear ubiquitin accumulation may remain restricted to CTIP2/SATB2 co-expressing 
neurons, as initial observations at DIV15 showed only a minority of this population to be 
vulnerable (Chapter III). This would strengthen the idea that a specific process unique to 
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these cells requires torsinA function. Another possibility is that ubiquitin accumulation 
expands to affect other cortical cell types. This result would suggest initial studies reflect 
a more global requirement for torsinA function and could hint at a maturation state-
related mechanism. Along these lines, torsinA LOF phenotypes (ubiquitin accumulation, 
nuclear pore complex disorganization) appear in vitro as early as DIV5. It remains to be 
determined which cortical cell types are showing defects at this early time point. 
Characterizing the timeline of this phenotype in vitro should help to define the 
developmental window that requires torsinA function.  
Ultrastructural investigation of diffusion tensor imaging (DTI) MRI studies 
Diffusion tensor imaging (DTI) MRI studies found that asymptomatic human carriers and 
our germline heterozygous mice (normal motor phenotype) display two DTI detected 
lesions (Carbon et al., 2004; Trost et al., 2002; Ulug et al., 2011). These lesions are within 
the thalamocortical and cerebellothalamic white matter connections. Meanwhile, DYT1 
patients were found to only exhibit the cerebellothalamic white matter lesion. These data 
suggest the “second hit” (forebrain abnormality) is protective and prevents abnormal 
cerebellar dysfunction from reaching output motor nuclei. This data led us to test the 
hypothesis that aberrant motor signals in DYT1 dystonia are originating in hindbrain 
motor centers. Specifically, our study asked whether a DYT1 hindbrain is sufficient to 
generate an overt motor phenotype in the context of normal forebrain circuitry. By 
selectively inducing the DYT1 genotype in the hindbrain using En1 Cre recombinase and 
our conditional knock-in mouse model we found that this configuration is not sufficient 
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to produce an overt motor behavior or neuropathology (Chapter II). Importantly, we 
know from previous conditional knockout models that this Cre driver hits a vulnerable 
population (deep cerebellar nuclei) and initiates recombination early enough (in neural 
progenitors) to delete torsinA during a critical neurodevelopment window (Liang et al., 
2014). Our findings lead us to reject our hypothesis and suggest DTI MRI findings may 
actually represent compensation events that do not relate to the manifestation of DYT1 
dystonia. Going forward, the results of this study challenge the field to investigate what 
DTI-detected alterations mean in regards to physical changes in the brain.  
In order to further investigate the DTI findings and ascertain what these imaging results 
mean in regard to physical changes in the brain we could pursue a transmission electron 
microscopy (TEM) study to evaluate axon integrity. Axon integrity can be quantified at 
the ultrastructural level via measurements of g ratio (radius of the axon / the radius of the 
axon + myelin sheath) and the number of axons myelinated. This TEM study would 
require examination of germline heterozygous mice originally evaluated using DTI MRI 
(Ulug et al., 2011), our hindbrain specific mutants (En1 Cre+ Tor1aSwap/+ = Tor1ai-∆E/+ in 
hindbrain structures), and the appropriate littermate controls. Germline heterozygous 
mice should represent a positive control for the DTI-detected lesions, meaning we should 
find defects in axon integrity that represent both “hits” (thalamocortical and 
cerebellothalamic) when compared to control brains. We predicted that inducing the 
DYT1 genotype in the hindbrain would eliminate the forebrain “protective lesion.” 
Therefore, in hindbrain specific DYT1 mice we would expect to find only defects in 
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cerebellothalamic connections. Since these mice did not exhibit overt motor behavior 
(Chapter II), TEM results may phenocopy those of germline heterozygous mice (two 
lesions). A preserved forebrain lesion in our hindbrain specific DYT1 mutant would 
suggest that these DTI detected abnormalities are not a cell autonomous event and arise 
due to an abnormal circuitry. Although this study could reveal why we did not generate a 
mouse with an abnormal motor phenotype, it is possible we will be unable to visualize 
histological evidence that supports DTI findings using this technique. If we are unable to 
distinguish between genotypes using these methods it should caution future work to rely 
on this technology until the impact of these findings can be substantiated in the mouse. 
  
Molecular consequences of torsin LOF 
The basis and impact of perinuclear ubiquitin accumulation in conditional mouse models 
remains to be understood. Ubiquitin is used as a signal for protein degradation via the 
ubiquitin proteasome system (Ciechanover & Kwon, 2015). Ubiquitination takes place at 
the ER membrane through ER associated degradation (ERAD) machinery and torsinA is 
linked to ERAD pathways (Nery et al., 2011). In addition, HRD1, an ERAD associated 
E3 ubiquitin-protein ligase is observed to mislocalize to the NE in conditional Tor1a LOF 
mouse models (Liang et al., 2014). Technical issues have prevented me from visualizing 
HRD1 localization in my cell culture model, however probing this pathway is likely to 
result in a clearer understanding of torsinA biology. Perinuclear accumulation of ubiquitin 
aggregates was observed in an unrelated mouse model of NF-Y inactivation (Yamanaka 
et al., 2014). NF-Y is a transcription factor believed to have a role that is specific to post-
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mitotic cells. This model also displays neurodegeneration, although unlike Tor1a LOF 
mouse models, cell death is progressive. Interestingly, the perinuclear ubiquitin 
accumulation was found to coincide with considerable ultrastructural changes to the ER, 
leading the authors to establish a role for NF-Y in ER maintenance. Ultimately, a major 
push for the DYT1 field should be to establish the molecular consequences of perinuclear 
ubiquitin accumulation. To study the impact of this phenotype, Tor1ab null neurons can 
be used for preliminary work due to the homogenous nature of the culture. Once 
pathways are identified, validation should take place in Tor1a null cultures and in vivo. In 
above sections, I described experiments that can address whether neurons with ubiquitin 
accumulation are dying or if they are able to resolve this phenotype. If we find that 
neurons are dying, it will be important to determine if ubiquitin accumulation is a 
contributing factor. One avenue to potentially investigate this link is to look for signs of 
ER stress, a pathway already linked to torsin proteins (Caldwell et al., 2003; Cao et al., 
2005; Chen et al., 2010). Determining whether this phenotype affects nucleocytoplasmic 
transport or nuclear pore kinetics will also be valuable.  
I observed striking differences in KDEL staining in Tor1ab null neurons compared to 
controls (Chapter III). KDEL (Lys-Asp-Glu-Leu) is the signal sequence that is common 
to ER resident proteins. This sequence is recognized by KDEL receptors which retrieve 
ER proteins from the Golgi apparatus and bring them to the ER. Perinuclear KDEL 
staining observed in Tor1ab null neurons could signify a failure in this signaling pathway. 
Like torsinA, KDEL receptors are linked to ER quality control pathways and cells that 
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express mutant KDEL receptors are more susceptible to ER stress because they cannot 
adequately recruit the molecular chaperones required for handling misfolded proteins 
(Capitani & Sallese, 2009). Interestingly, a mouse expressing a dominant negative KDEL 
Receptor mutant was observed to display ubiquitin aggregation (Hamada et al., 2004). 
Tor1ab null cells displayed normal staining of integral ER membrane protein calnexin, 
suggesting overall ER morphology is normal. ER morphology abnormalities were never 
observed during electron microscopy studies of NE budding, however a dramatic 
reorganization of the ER was found in a cell line that models torsinB LOF (Rose et al., 
2014). To understand what abnormal KDEL staining means for this culture, this 
phenotype should be examined using the localization of other ER proteins and by 
evaluating the ultrastructure of these neurons using electron microscopy.  
The rate of nuclear pore complex (NPC) insertion increases dramatically during 
development in order to provide the necessary nucleocytoplasmic transport required for 
adequate mRNA export and protein synthesis (Dauer & Worman, 2009). It remains to be 
determined if torsinA plays a role in NPC insertion, however I observed NPC 
disorganization in Tor1ab null (Chapter III) and in Tor1a null cultures. The antibody I 
used to label NPCs (mab414) is specific to nucleoporins (Nups) with FG (phenylalanine-
glycine) repeats. Nups are a diverse group of proteins that form the nuclear pore complex 
(~30 Nups) (Wente & Rout, 2010). Torsin ATPases have been linked to the 
mislocalization of specific Nups in C. elegans (VanGompel et al., 2015). Van Gompel 
and colleagues found that Nup mislocalization into large plaques followed a 
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developmental time course. One of the implicated Nups in their work, NPP-9, is 
conserved in mammals and is one of the FG repeat-Nups labeled in my study (Galy et al., 
2003; Aris & Blobel, 1989)). A strikingly similar abnormal staining is observed in C. 
elegans after knockdown of two Nups (Nup93 and Nup205) required for normal NPC 
distribution (Galy et al., 2003). Taken together, this data further implicates a role for 
torsinA in the proper localization of NPCs. The diverse family of Nup proteins should be 
considered when looking for substrates of torsin ATPases.  
Many of our in vivo observations coincide with circuit integration and the onset of 
neuronal activity (Liang et al., 2014; Pappas et al., 2015). A potentially interesting set of 
experiments using my in vitro model could address the role neuronal activity plays in 
ubiquitin accumulation. If we block neuronal activity using pharmacological 
interventions, we could ask whether neuronal activity is required for the generation of 
these anomalies. We could also ask whether enhancing neuronal activity worsens or 
alleviates torsin LOF phenotypes. Investigating NPC distribution in the same experiments 
would also be interesting because synaptic stimulation is sufficient to cause an 
upregulation of NPC insertion (Wittmann et al., 2009). 
The NE budding phenotype observed in conditional mouse models of Tor1a LOF (For 
example see Figure II.1 or (Goodchild et al., 2005)), is hypothesized to reflect the stalling 
of a recently defined nuclear export mechanism. This process allows for large bundles of 
translationally silent ribonucleoprotein particles (megaRNPs) to exit the nucleus via 
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budding of the NE and is critical for localized protein synthesis (Speese et al., 2012). 
Torsin ATPases are linked to megaRNP export in drosophila (Jokhi et al., 2013). Jokhi 
and colleagues demonstrate that torsin mutants exhibit abnormal synapse development 
due to defective protein synthesis. Whether the disorganized NPC staining I observed in 
vitro is a reflection of the torsinA LOF-specific NE abnormality, NE budding, remains an 
unclear but intriguing area of interest (Chapter III). There is currently no evidence to 
support a link between NE budding and NPCs. This  suggests other NE markers should 
be used to investigate NE budding in my culture system.  
To date, the field has lacked the genetic and microscopy tools required to resolve the NE 
budding phenotype using traditional immunocytochemistry methods. Advancement in the 
field of super resolution confocal microscopy moves us closer to visualizing this 
phenomenon using immunostaining of NE proteins (Eggeling et al., 2013). For example, 
the Leica SP8 TCS g-STED 2 photon confocal microscope used for analysis of Tor1ab 
null cultures in Chapter III is reported to visualize cellular morphology as small as 50 nm 
(http://www.leica-microsystems.com/products/confocal-microscopes/details/product/
leica-tcs-sp8-sted-3x/). This is within the size of NE buds observed in conditional mouse 
models (Goodchild et al., 2005). Therefore, with the correct molecular markers it may be 
possible to observe NE budding using my in vitro model. One method worth 
investigating is an approach that requires live-imaging. Incorporation of a spectral shift 
dye, FM4-64, allows for specific labeling of the NE (Zal et al., 2006). Using this dye, Zal 
and colleagues were able to observe NE convolutions in cancer cells. MegaRNP export 
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has yet to be studied in a mammalian system. Whether it is through new methods using 
super resolution confocal microscopy or traditional electron microscopy, Tor1ab null 
cultures provide the necessary model to ask if this is a conserved cellular process and in 
what manner torsin ATPases participate. 
In vivo validation and exploration of CTIP/SATB2 vulnerability  
Cell-type specific susceptibility is a hallmark of many neurodegenerative diseases and 
has recently been recognized as a possible feature of DYT1 dystonia pathogenesis 
(Pappas et al., 2015; Liang et al., 2014). Determining a specific cortical cell type 
vulnerable to torsinA LOF not only aids molecular studies by concentrating analysis on a 
relevant population, but also sheds light on what circuit abnormalities could be 
contributing to abnormal motor behavior observed in disease manifesting mice. I 
identified neurons co-expressing transcription factors CTIP2 and SATB2 to be distinctly 
susceptible to torsinA LOF at DIV15 (Chapter III). This suggests that a specific subset of 
layer 5 pyramidal neurons require torsinA function during this time, however the fact that 
this is a dissociated cortical culture eliminates information on the true layer of origin for 
these neurons (Fame et al., 2011). In addition, these transcription factors are not 
commonly expressed simultaneously. SATB2 acts to downregulate the expression of 
CTIP2 in order to direct development of callosal projections (Alcamo et al., 2008; Leone 
et al., 2014). 
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In order to verify that CTIP2/SATB2 co-expressing neurons are specifically susceptible 
to Tor1a LOF, co-labeling needs to be performed on mouse brain tissue in conjunction 
with the ubiquitin antibody. Due to the dichotomy between projection targets of CTIP2+ 
and SATB2+ neurons, retrograde labeling experiments will further elucidate the 
vulnerable cortical neuron population. SATB2 neurons innervate the contralateral 
hemisphere in a homotopic manner, thus injection of fluorescent molecules into layer 5 
should retrogradely label layer 5 SATB2+ neurons in the contralateral hemisphere 
(Leyva-Diaz & Lopez-Bendito, 2013). CTIP2+ neurons traditionally target subcortical 
nuclei including the spinal cord (Molnar & Cheung, 2006). Retrograde labeling 
experiments are the gold standard in the field of defining subcortical neuronal 
populations and initial immunohistochemical investigations should inform us on the 
necessary timing for these studies. After validation in vivo, we can begin to ask why this 
population is more vulnerable compared to others. We can also investigate the molecular 
consequences of torsinA LOF in this population. For example, labeling the affected 
population using genetically driven fluorescent reporters will allow us to look at 
somatodendritic morphology and electrophysiological properties. This line of 
experiments will bring us closer to understanding circuit changes taking place that lead to 
abnormal motor output in Tor1a LOF mouse models. 
Looking Ahead 
There are several important challenges that must be met in order to develop better 
therapeutics for DYT1 dystonia patients. The first is establishing physiological substrates 
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for torsinA:LAP1 (or LULL1) ATPases. This will likely require more biochemical work 
and proteomics studies with an emphasis on recently identified neuronal populations that 
are distinctly vulnerable to torsinA LOF. Secondly, now that we have established several 
torsinA LOF mouse lines that develop motor behaviors characteristic of the human 
disease state, we need to define the neurophysiological abnormalities present in these 
mice. A recent collaboration allowed our lab to begin to understand circuit changes in one 
line of mice (Pappas et al., 2015), however much greater detail is needed. In addition, 
these findings must be expanded to include other lines in the lab in order to truly 
understand the impact of torsinA LOF on neurophysiology. Finally, to accurately develop 
therapeutics that could aid DYT1 Dystonia patients, we must determine the 
developmental timeline of neurological changes that lead to dystonia symptoms. For 
example, if all torsinA LOF damage occurs during embryonic development, our 
treatments should be focused on restorative mechanisms. If the DYT1 mutation results in 
changes throughout childhood including times when patients manifest the disease, we can 
consider preventative measures. This approach requires the added issue of defining the 
mechanisms that control disease penetrance. Tackling these three themes should prove 
beneficial for helping DYT1 patients and provide insight into disease mechanisms 
underlying other forms of dystonia. 
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